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ABSTRACT 
The regulation of gastric acid secretion is complex and involves endocrine, paracrine, and 
neurocrine mechanisms. Among these, the interconnecting cross-talk between different gut 
peptides is an important part in the control of acid secretion. 
The aims of this thesis were (1) to develop a new method of measuring intragastric pH for 
prolonged periods of time, and (2) apply developed and in-use methods using different 
substances and their impact on gastric acid secretion in vivo experiments on rats. (3) To study 
the changes in acid output and the migrating motor complex (MMC) when subjected to 
different substances, and (4) to further study the alterations in expression of different gut 
peptides in tissue samples in vitro, and the impact of inflammation in the gut. 
 
The novel Bravo model developed gave reliable recordings compared to the chronic fistula 
model. The pH rose during treatment with esomeprazole and the acid output in the fistula 
model decreased accordingly. Gut peptides ghrelin and somatostatin increased in plasma when 
subjected to esomeprazole treatment, while gastrin remained unchanged. Ghrelin administered 
in bolus doses increased the intragastric pH in accordance with previous experiments. 
 
The gut peptides somatostatin, neurotensin, and vasoactive intestinal peptide increased during 
pentagastrin-stimulated infusion and challenge with hydrochloric acid and polyethylene glycol 
both in plasma and intestinal perfusate, though the most pronounced elevation was seen in 
perfusate and with somatostatin. Gastrazole gave the most extensive inhibitory effect on acid 
secretion compared to ranitidine and esomeprazole. 
 
The CCK2-receptor antagonist YF476 inhibited acid secretion long-term and increased 
concentrations of ghrelin and somatostatin in plasma, but gastrin remained low. Tissue mRNA 
content of the peptides and their receptors were unchanged except for the ghrelin receptor. 
When subdued to NSAID gastrin, CCK2-receptor and iNOS increased in mRNA expression 
while other peptides and receptors were unchanged.  
 
Administration of NPS evoked a response in the MMC pattern with irregular spiking and 
prolonged cycle length of the activity fronts, and the mRNA expression of iNOS, TNF, and IL-
1β increased in the tissue. 
 
In conclusion, The Bravo model can be used as a complement to the chronic fistula model for 
measurements of pH. The regulation of gastric acid secretion is not only limited to the stomach, 
but also present in the smaller intestine where release of somatostatin seems to be most 
important. Different mechanisms are involved in the blockage of acid secretion when subjected 
to YF476, but under NSAID treatment the expression of gastrin and its CCK2-receptor increase 
and COX-2 is activated which demonstrates a novel pathway for the study of gastric 
ulcerations. NPS, a novel neuropeptide influences the gastric motility and could have a role in 
inflammatory responses seen in the changes in the migrating motor complex and inflammatory 
markers iNOS, TNF, and IL-1β. 
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1 Introduction 
 
1.1 Gastric acid 
Up to the present day the study of gastric acid and its secretion and regulation, and our 
understanding of its relation to physiological and pathophysiological conditions are 
considerable. It ranges from Hippocrates (460-377 B.C.)1 to modern times with the discovery of 
the so called conditioned reflexes by Ivan P. Pavlov during the 19th century2, gastrin as the main 
stimulant of gastric acid secretion by John Edkins 19053, and James W Blacks discovery of the 
H2-receptor in 1972 just to mention a few4.  
Gastric acid enables the digestion of protein and absorption of iron, calcium and vitamin B-12. 
It also prevents bacterial overgrowth and infections in the intestines5. The secretion must be 
regulated precisely not to cause ulceration6 and maldigestion7. This regulation is highly 
complex and involves hormonal, neuronal, and paracrine mechanisms. 
 
1.1.1 Functional anatomy of the stomach 
The stomach consists of three distinct anatomical parts, fundus, corpus (or the body) and 
antrum, and two functional parts, the pyloric and oxyntic glands (figure 1). 
 
 
Figure 1. Schematic illustration of the stomach (lithography originally published in 1918 in Grey´s 
anatomy). 
 
Fundus and corpus comprises 80% of the total organ and consists of the oxyntic or parietal 
cells, and the rest is composed of the antrum part in which the G-cells, or gastrin producing 
cells resides. It is estimated that the human stomach consists of 1x109 parietal and 9x109 gastrin 
cells8(figure 1). 
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Figure 2. Anatomy of the gastric (oxyntic and pyloric) gland region in the mucosal lining of the stomach 
(reprinted with permission from the publisher, Mitchell L. Schubert).  
 
One of the most prominent cell type in the oxyntic glands is the acid-secreting parietal cells9 
and the, at the base predominant zymogenic (chief) cells which secretes pepsinogen10, 11 and 
leptin12. In addition to these cells the glands also contain neuroendocrine cells hosting a wide 
range of potential paracrine and hormonal signaling agents. A few of these have been identified 
as having physiological functions: (1) D cells containing somatostatin and amylin13, 14; 
enterochromaffin-like (ECL) cells containing histamine15; X/A-like or Gr cells containing 
ghrelin and obestatin16, 17; and enterochromaffin (EC) cells containing serotonin, 
adrenomedullin, and atrial natriuretic peptide (ANP)18-20. The pyloric glands contain D cells, 
X/A-like or Gr cells, and EC cells as do the oxyntic glands. In addition they also contain 
endocrine cells harboring orexin21, and the gastrin-secreting G cells (figure 2).  
 
1.1.2 Neuronal anatomy of the stomach 
The stomach and the intestines are richly innervated with nerves and neuronal messengers in a 
system called the enteric nervous system (ENS). The ENS is made up of intrinsic and extrinsic 
afferent and efferent neurons distributed in two major complexes – the myenteric and 
submucosal plexuses22. The nerves and messengers serve such functions as gastrointestinal 
motility, acid secretion, hormone release, blood flow and mucosal defense mechanisms23. The 
ENS is part of the autonomic nervous system, which also includes the sympathetic and 
parasympathetic system, and is often referred to as the little brain24. This is because of its 
relative independence from the central nervous system (CNS).  
The efferent nerve fibers are preganglionic and are connected to postganglionic neurons in the 
ENS. Unlike the preganglionic fibers the postganglionic directly innervate the target cells, i.e. 
the neuroendocrine and parietal cells. The postganglionic neurons contain a number of 
neurotransmitters, including acetylcholine (ACh), vasoactive intestinal polypeptide (VIP), and 
nitric oxide (NO) among others. These neurons regulate gastric acid secretion directly, via ACh 
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or indirectly through the action of gastrin from G cells, somatostatin from D cells, histamine 
from ECL cells, and ANP from EC cells25, 26. 
 
1.2 Regulation of gastric acid secretion 
The hydrochloric acid is secreted by the parietal cells in the oxyntic glands (figure 2) and is 
assumed to reach the lumen of the stomach through the mucus layer by the relatively high 
intraglandular pressure generated during secretion. The parietal cells possess three different 
acid stimulatory receptors: CCK2-receptor (CCK2R), histamine 2 receptor (H2R), and 
muscarinic 3 receptor (M3R). There appears to be two main cellular mechanisms or pathways of 
acid secretion in the parietal cells: (1) activation of H2R by histamine and subsequent increase 
in 3´-5´-cyclic adenosine monophosphate (cAMP) content in the parietal cells, and (2) 
activation of CCK2R by gastrin and M3R by acetylcholine (released from the parasympathetic 
nerve terminals) which stimulate increase in calcium concentration27, 28 (figure 4). The secreted 
acid has a concentration of about 160 mmol L-1 or pH 0.829. This is implemented through a 
series of complex interactions that are activated either directly through stimuli originating in the 
brain or through stimuli originating in the stomach, such as acid, distension, or protein28 (figure 
3). 
 
Figure 3. Schematic illustration of control of gastric acid secretion. 
 
1.2.1 Gastrin 
The peptide hormone gastrin is the main acid stimulatory agent during ingestion of a meal30. 
Gastrin is released from G cells in the antrum in an endocrine fashion and stimulates the 
parietal cells directly to produce gastric acid or indirectly through the release of histamine from 
the ECL cells. Gastrin binds to the CCK2R located both on the parietal as well as the ECL cells 
  - 4 -  
and activates a signaling cascade involving phospholipase C and release of intracellular 
calcium31-33. Although it is still not entirely clear if the direct effect of gastrin on the parietal 
cells is true34, 35, it is believed that intracellular concentrations of cAMP have to reach a 
particular threshold for gastrin to be able to directly stimulate the parietal cells36. The primary 
action of gastrin on the parietal cells seems to involve sensitizing them to other secretagogues 
through synergistic interactions between signaling pathways. Presently the main mechanism by 
which gastrin is thought to stimulate gastric acid secretion is through the activation of CCK2Rs 
on the ECL cells and following stimulation of histamine release33, 37. Gastrin also has trophic 
effects on the oxyntic mucosa and stimulates migration of gastric epithelial cells through their 
action on CCK2R31, 38, 39. 
 
1.2.2 Histamine 
Histamine is like gastrin one of the principal stimulants of gastric acid secretion. Released from 
the ECL cells they exert their action in a paracrine manner, stimulating acid secretion through 
H2-receptors on the parietal cells40. Histamine also binds to H3-receptors and indirectly 
stimulates release of acid by inhibiting somatostatin41. 
 
1.2.3 Somatostatin 
Somatostatin is a powerful physiological inhibitor of gastric acid secretion5. Somatostatin has a 
widespread distribution throughout the central nervous system (CNS) and different peripheral 
tissues and organs42-45. In the stomach somatostatin is synthesized and released from 
cytoplasmic processes of the D cells of the fundic and antral mucosa46. These processes are in 
close contact with their target cells (e.g. gastrin, ECL, and parietal cells), and although 
somatostatin also is secreted via the local circulation and indirectly acts on its target, 
somatostatins main mode of action seems to be paracrine rather than endocrine47-50. In the 
stomach the action of somatostatin is mediated by somatostatin subtype 2 receptor (SSTR2)51, 52 
by inhibiting acid secretion from the parietal cells and reducing the concentrations of circulating 
histamine and gastrin44, 53-55. 
 
1.2.4 Ghrelin 
The stomach is the predominant source of circulating ghrelin56, 57. Production of ghrelin has 
been localized in the X/A or Gr cells of the oxyntic mucosa58-60 but is also found in various 
other tissues and organs57, 61. Ghrelin binds and exert its actions via the orphan growth hormone 
secretagogue receptor type 1a (GHS-R1a)62 that is highly expressed in hypothalamus, the 
pituitary and stomach, consistent with its influence on energy balance, food intake and appetite 
control63-68. Several other tissues and organs also house the GHS-R1a indicating broader 
functions of ghrelin other than food intake and growth hormone release69-72. Ghrelin levels are 
decreased by ingestion of food and increased by restriction of energy suggesting that ghrelin 
secretion is controlled by metabolic signals73, 74. Ghrelin has been reported to stimulate acid 
secretion75, 76 which seems to involve the vagus nerve77 and histamine release78, although one 
study showed no effect on basal secretion and a decrease in pentagastrin-stimulated acid 
secretion in conscious rats with gastric fistula79. Furthermore, ghrelin secretion has shown to be 
inhibited by activation of somatostatin receptors. When native somatostatin or synthetic 
analogues such as octreotide were given in pharmacological doses there was a pronounced 
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reduction in circulating ghrelin. On the other hand ghrelin increases circulating somatostatin 
implicating a feedback mechanism between these peptides76, 80, 81. 
 
1.2.5 Neuropeptide S 
Neuropeptide S (NPS), a novel neuropeptide first described in the patent literature82, binds to a 
G-protein coupled receptor – neuropeptide S receptor (NPSR1) – and induces elevation of 
intracellular Ca2+ and cAMP83-85. NPS is involved in anxiety, food intake, sleep, pain, and 
modulation of stress responses83, 86-91. NPS and its receptor is primarily expressed in different 
regions of the brain92, but recent data also indicate a strong expression pattern of NPSR1 and its 
ligand in the enteroendocrine cells of ileum, duodenum, colon and rectum, and in the 
submucosal neurons93 suggesting a role for NPS-NSPR1 in gastrointestinal motor and sensory 
functions. One other peripheral cell type reported to be sensitive to NPS are the macrophages, 
which responds to NPS with reduced adhesion, increased phagocytosis, and chemotaxis94. 
Immunological responses involving NPS and macrophages have been suggested in skin and in 
the intestine95, indicating that the NPS–NPSR system may have a role in modulating innate 
immunity and chronic inflammatory diseases of epithelial barrier organs96, 97. 
 
1.3 Pharmacology and acid secretion 
A large body of work has been done during several decades to develop pharmacological 
treatments for the prevention of acid related disorders4, 98-100. Our comprehension of acid-peptic 
disorders was revolutionized with the discovery of the proton pump in the parietal cells 
(hydrogen-potassium adenosine triphosphate; H+K+ATPase) and Helicobacter pylori (HP) 
infections as the dominant cause of gastric and duodenal ulcers101-104. Now the development of 
the proton pump inhibitors (PPIs) became the focus of acid-related disease treatment, although 
better therapies are needed to eradicate for example night-time reflux, symptoms related to 
endoscopic-negative reflux disease, and extraesophageal manifestations of GERD105. 
 
1.3.1 Proton pump inhibitors 
Since the discovery of omeprazole in 1987105 proton pump inhibitors (PPIs) have been the gold 
standard for treatment of acid-related diseases106. The PPIs belongs to a group of so-called 
substituted benzimidazole derivatives and are weak bases accumulating in the acid 
compartments of the parietal cells. There, they undergo conversion from inactive to active form 
driven by the low pH in the cells. When in an active form the PPIs, such as omeprazole (Losec) 
or esomeprazole (Nexium), irreversibly and selectively bind to the gastric proton pump (H+, K+-
ATPase) that drive the final step in acid secretion107 (figure 4). PPIs are the treatment of choice 
in disorders such as peptic ulcer, gastrointestinal (GI) lesions, gastrooesophageal reflux 
disease (GERD), nonsteroidal anti-inflammatory drug (NSAID)-induced, dyspepsia, 
Zollinger-Ellison syndrome, and eradication of HP106, 108-110. 
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Figure 4. Illustration describing various receptor antagonists on the parietal and ECL cell. 
 
1.3.2 H2-receptor antagonists 
The parietal cell possesses histamine H2Rs. Stimulated by histamine, in response to release of 
gastrin from G cells these receptors then signals the subsequent secretion of gastric acid28, 111. 
Since the groundbreaking discovery of H2-receptors and receptor antagonism4, several 
histamine-like antagonists have emerged on the market. These have been used primarily in the 
treatment of peptic ulcers, but are also common as a combinatory treatment regime together 
with PPIs112-115. The H2R antagonists block the histamine-driven stimulation of adenylate 
cyclase and generation of cAMP in the parietal cells. Acetylcholine and gastrin are capable to 
release histamine from ECL-cells and interacts in synergy with histamine to stimulate acid 
secretion; therefore the H2R antagonists, such as ranitidine, inhibit all modes of stimulation by 
eliminating the direct and synergistic actions of histamine112, 116 (figure 4). 
 
1.3.3 CCK2-receptor antagonists 
The ECL cells in the oxyntic mucosa are rich in CCK2R117-119 and operate under control of 
gastrin, establishing the gastrin-ECL cell axis120, 121. As mentioned above, gastrin, histamine, 
and ACh are recognized as physiological stimulants of gastric acid secretion. There is some 
debate which specific pathways that control acid secretion from the stomach, but it seems 
accepted that gastrin stimulate acid secretion by mobilizing histamine from ECL cells which in 
turn stimulate parietal cells to produce gastric acid122-126. The CCK2R antagonists have proven 
to inhibit the enzyme responsible for producing histamine, histidine decarboxylase (HDC), 
which is stimulated by means of gastrin on the CCK2R127-129. Understandably, the inhibition of 
(esomeprazole)
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gastric acid secretion with CCK2R antagonists, such as YF476 or gastrazole, is a result of 
inhibition of histamine release from the ECL cells (figure 4). 
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2 Aims 
The overall aim of this thesis was to study the effect of acid inhibition on gut peptide regulatory 
mechanisms in physiological and inflammatory reactions in vivo and in vitro. The more specific 
aims were: 
 
 
• To develop a new model to study intragastric pH over prolonged periods of time using 
an implanted pH sensor. 
• Apply developed and in-use methods using different substances and their impact on 
gastric acid secretion in vivo experiments on rats  
• Study the changes in acid output and the migrating motor complex (MMC) when 
subjected to different substance 
• To further study the alterations in expression of different gut peptides in tissue samples 
in vitro, and the impact of inflammation in the gut  
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3 Material and Methods 
 
3.1 Ethics approvals 
For all projects included in this thesis, ethics approval was granted by the Animal Ethics 
Committee in northern Stockholm (Stockholm, Sweden). Paper I (D no: 157/05, and 100/07), 
Paper II (D no: 297/90, 157/05, and 100/07), Paper III (D no: 157/05, 100/07, 191/08, and 
353/09), and Paper IV (D no: 226/09, and 348/09). 
 
3.2 Animals 
For Paper I-IV, Sprague-Dawley (SD) male rats (300 g – 350 g) were purchased from Scanbur 
B&K AB (Sollentuna, Sweden) or Charles River (Kisslegg, BW, Germany).. The animals were 
fed ad libitum with a commercial rat diet (LABFOR, Lactamin R36, Kimstad, Sweden) and tap 
water. 
 
3.3 Bravo capsule method (paper I and III) 
In paper I we developed a new method for measuring intragastric pH based on the Bravo 
technique used in clinical setting. BravoTM module is a catheter-free intragastric pH 
registration system which utilizes telemetric transference (figure 5).  
 
 
Figure 5. Picture of a Bravo pH registration module in a closed and opened mode. 
 
 
A pre-calibrated (buffers pH 1.07 and 7.1) Bravo capsule (an electronic sensor encapsulated in 
PVC-plastic, 25x5x5 mm; Synmed Medicinteknik AB, Spånga, Sweden) is placed inside the 
stomach of the rat (figure 6).  
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Figure 6. Picture of a Bravo capsule (measurements 25x5x5 mm). 
 
 
The pH recorded by the Bravo capsule is transmitted to the Bravo receiver placed directly 
outside the rat’s cage. The sampling frequency is 6 Hz and set for a 48-h registration period 
after which the data has to be downloaded, batteries replaced recording continued. This 
procedure can then be repeated in two more 48-h periods before the battery of the capsule 
finally runs out and has to be replaced by a new one. 
For the Bravo system studies in papers I and III a midline incision was done, and a small 
opening created in the proximal greater curvature and the Bravo capsule was placed inside the 
stomach with the pH sensor pointing distally and anchored with a suture (figure 7). 
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Figure 7. Pictures of the surgical procedures involving the Bravo capsule in the rat. (A) A midline 
incision was done and the stomach uncovered (B). An opening of the stomach was created, the gastric 
content removed and the capsule placed inside attached with a suture (C). The stomach was then sutured 
together as the midline incision and skin (D and E). The pH measurement was started (F) and the animal 
was placed in its cage to recover before the commencement of the experiment. 
 
 
An indwelling catheter (Dow Corning Co., Midland, MI, USA) was inserted into the external 
jugular vein for injection of drugs or saline. Studies of intragastric pH began in the morning 2 
days after surgery, and were carried out in conscious rats under normal conditions, or after a 16-
h fasting period with free access to water. The animals gained weight and behaved in a normal 
fashion throughout all the experiments. At post-mortem examination, no mucosal lesions, 
obstruction of the pylorus or gastric distension were seen.  
 
3.4 Chronic gastric fistula (paper I and II) 
For the gastric fistula experiments animals were provided with a plastic cannula (a gastric 
fistula) placed proximal to the oxyntic gland area, and an IV catheter (Dow Corning Co.) 
implanted into the external jugular vein for drugs and infusion of saline and pentagastrin. After 
surgery and in between experimental periods the cannula was closed to prevent leakage. The 
animals recovered for at least 7 days after surgery before the commencements of the 
experiments. Prior to each experiment food was withheld for 18 h, but with free access to water. 
The stomach was rinsed with 10-15 ml luke-warm tap water to evacuate remaining food 
followed by a 30-min period before experiments were started. During the experiments, the 
conscious rats were placed in Bollman cages, and the gastric juice was collected at 30-min 
intervals. Volumes were measured to the nearest 0.1 ml and hydrogen ion concentration (pH) 
calculated by back-titration using 0.1 M sodium hydroxide. Acid output was calculated by 
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multiplying the secretion volumes with hydrogen ion concentrations and expressed as μmol per 
30-min period.  
 
3.5 Thiry-Vella loop (paper II) 
After an overnight fast (18 h), the rats were anesthetized with pentobarbital (50 mg kg-1 
intraperitoneally (IP), Apoteksbolaget, Umeå, Sweden) and a 10 cm long Thiry-Vella loop of 
the jejunum was prepared in each rat by dividing the duodenum at the pylorus and 6 cm farther 
distally, at the ligament of Treitz. A 10 cm long part of jejunum was removed immediately 
distal to the ligament of Treitz and a blind loop was constructed. To restore gastrointestinal 
continuity the continuous proximal and distal parts of the jejunum were anastomosed end-to-
end. The oral end of the Thiry-Vella loop was closed, intubated with a catheter (PE 90, Clay 
Adams & Co., Becton Dickinson, Parsippany, NJ, USA), and attached to the abdominal wall. 
The distal end was brought through the abdominal wall and tunnelled subcutaneously to the 
back of the animal´s neck. Then, a mid-segment of the duodenal loop, 5-7 mm long, with the 
orifices of the bile and pancreatic ducts, was implanted end-to-side to the jejunum as a pouch 
10 cm distal to the entero-anastomosis of the duodenum (figure 8).  
 
 
 
 
 
 
 
 
 
Figure 8. Schematic drawing of a Thiry-Vella loop 
of the proximal jejunum with duodenum, bile and 
pancreatic ducts anastomosed as a blind loop to the 
jejunum. 
 
 
 
 
 
 
 
 
The rats had free access to water 24 h after surgery and access to food on the second 
postoperative day. A siliastic catheter (Dow Corning Co.), pretreated with heparin was inserted 
into the jugular vein for blood sampling and administration of saline and pentagastrin. 
Throughout the experiments saline was initially administrated via the jugular vein catheter for 
120 min by an infusion pump (Sage Instruments, Cambridge, MA, USA). Pentagastrin (90 
pmol kg-1min-1) was then added to the IV saline infusion for the remaining 90 min. In control 
experiments, the intestinal loops were perfused with 154 mmol L-1 NaCl at a rate of 2 ml h-1. 
Proximal 
jejunum 
10 cm
 
Bile 
duct 
Duodenum
20cm
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In test experiments, either hydrochloric acid, HCl (200 mmol L-1; pH 1.1; 380 mOsm kg-1) or 
polyethylene glycol, PEG (1200 mOsm kg-1; pH 7.2), was given during the pentagastrin 
infusion period (60 min). The concentrations of HCl and PEG were chosen as they caused 
maximal inhibition of pentagastrin-stimulated acid secretion130. The luminal content was 
collected during the experiments and kept on ice before analysis of gut peptides SOM, 
neurotensin (NT), and VIP. 
 
3.6 Gastrointestinal motility in vivo in rats (paper IV) 
Surgery was performed in animals under anesthesia with a mixture of midazolam (5 mg ml-1, 
Aktavis AB, Stockholm, Sweden) and Hypnorm (fentanylcitrate, 0.315 mg kg-1 plus fluanisone 
10 mg kg-1; Janssen-Cilag, Oxford, CT, USA.) given subcutaneously (SC) at a dose of 1.5-2 ml 
kg-1 body weight. Temgesic® (Schering-Plough, Stockholm, Sweden) 0.05 mg kg-1 body 
weight was given SC after surgery to avoid post-operative pain. The abdomen was opened via a 
midline incision and three bipolar insulated stainless steel electrodes (SS-5T; Clark 
Electromedical Instr., Reading, UK) were implanted into the muscular wall of the small 
intestine, 5 (J1), 15 (J2) and 25 (J3) cm distal to the pylorus. The electrodes were tunneled to 
the back of the animal’s neck. All animals were supplied with an indwelling silastic catheter 
(Dow Corning Co.) inserted into the external jugular vein for intravenous (IV) administration of 
Neuropeptide S (NPS) (NeoMPS, Strasbourg, France), or saline solution (sodium chloride 9 g 
L-1; 300 mOsm kg-1 H2O, Fresenius Kabi, Halden, Norway). After surgery, the animals were 
housed individually and allowed to recover for at least 7 days before experiments were 
undertaken. Experiments were carried out in conscious animals after an overnight fasting period 
(18 h) in wire-bottomed cages with free access to water. During the experiments the rats were 
placed in Bollman cages, and the electrodes were connected to electroencephalography 
preamplifiers (7P5B) operating a Grass Polygraph 7 B (Grass Instr., Quincy, MA, USA). The 
activity front (phase III) of the MMC, was identified as a period of distinguishable intense 
spiking with an amplitude at least twice that of the preceding baseline and a frequency of at 
least 40 spikes min-1, propagating through the whole recording segment and followed by an 
inactive period, phase I of MMC. The cycle length, duration and propagation velocity of the 
activity fronts were calculated as a mean of the study period. The MMC cycle length, reflecting 
the interval between the propagated activity fronts was calculated at the J2 recording site. All 
experiments started with a control recording of baseline myoelectric activity with four regular 
MMCs propagating over all three recording sites. As the fifth activity front had vanished at the 
first electrode site, an IV infusion of either NPS, or saline solution was started using a 
microinjection pump (CMA 100; Carnegie Medicine, Stockholm, Sweden) and continued for 
60 min, until the basal MMC pattern returned. 
 
3.7 Gastric ulcer induction (paper III) 
The animals were deprived of food but with free access to water 20 hours before the ulcer 
induction. The experiments were carried out in conscious animals given either a single dose of 
isotonic saline solution (sodium chloride 9 g L-1; 300 mOsm kg-1 H2O, Fresenius Kabi, Halden, 
Norway), esomeprazole (140 mg kg-1; AstraZeneca, Stockholm, Sweden) or YF476 (100 mg kg-
1 dissolved in 0.5 % methyl cellulose) one hour prior to the administration of diclofenac, 30 mg 
kg−1. All substances were given via gavage and the animals left in their cages and at the end-
point, 4 hours after the final dose of diclofenac, the animals were sedated with CO2 and 
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euthanized by cervical dislocation. The abdomen was opened, the stomach removed and gently 
washed in phosphate buffer and spread open for photography. 
The ulcer index131 (expressed as mm) reflected the total length of gastric lesions per stomach as 
judged by three independent researchers blinded to the protocol. Tissue from the stomach was 
removed and placed in RNAlater (Ambion, Applied Biosystems, Carlsbad, CA, USA) for 
qPCR analysis. 
 
3.8 Blood sample collection 
Blood samples were withdrawn either from the jugular vein catheter during the experiments or 
full blood sampling by cardio puncture after sacrifice. Blood samples were centrifuged at 4° C, 
pipetted off and plasma collected. All samples were stored at -80°C until extraction procedures 
and radioimmunoassay (RIA). 
 
3.9 Radioimmunoassay (paper I-III) 
 
Paper I 
The ghrelin (active) radioimmunoassay kit (Linco Research, St. Charles, MI, USA) was used, 
which utilizes 125I-labeled ghrelin and ghrelin antiserum to determine active ghrelin in plasma. 
Intra- and interassay coefficients of variation were 7% and 14%.  
Gastrin was analyzed using C-terminal-directed CCK/gastrin antiserum 2609/10132. 
Chloramine-T-labeled and HPLC-purified gastrin-17 (NeoMPS) was used as ligand and 
gastrin-17 as calibrator/standard. Intra- and interassay coefficients of variation were 6% and 
8%. 
An EIA kit from Phoenix Pharmaceuticals, Burlingame, CA, USA) was used to analyze 
somatostatin, which reacts 100% to somatostatin-14 and somatostatin-28. Intra- and interassay 
coefficients of variation were 5% and 14%.  
 
Paper II 
SOM-like immunoreactivity (LI) was analyzed with a detection limit of 2 pmol L−1; intra- and 
interassay coefficients of variation were 7% and 11%133. 
NT-LI was analyzed using antiserum H which reacts with NT, NT (4–13) (118%), NT(8–13) 
(167%) and NT(9–13) (15%), but not with N-terminal fragments of NT. The detection limit of 
the assay was 8 pmol L−1. Intra- and interassay coefficients of variation were 8% and 13%134. 
VIP-LI was analyzed in plasma and perfusates using antiserum VIP2 raised against natural 
porcine VIP. Detection limit of the assay was 3 pmol L−1. Intra- and interassay coefficient of 
variation were 9% and 13%. 
 
Paper III 
The rat ghrelin (active) EIA kit (Millipore, Billerica, MA, USA) was used, utilizing 125I-labeled 
ghrelin and antiserum which reacts 100% to active ghrelin in plasma, but not inactive des-
octanoyl ghrelin. Intra-assay coefficient of variation was 7%. 
Gastrin was analyzed using antiserum the C-terminally-directed CCK/gastrin antiserum 
2609/10135. Chloramine-T labeled and HPLC-purified gastrin-17 (NeoMPS) was used as ligand 
and gastrin-17 as standard. The assay reacts 100% with gastrin-17 in plasma but not 
pentagastrin. The detection limit of the assay was 3 pmol L-1 and the intra-assay coefficient of 
variation 6%.    
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Somatostatin was analyzed using an EIA kit (Phoenix Pharmaceuticals), which reacts 100% to 
somatostatin-14, -25 and -28 in plasma. The intra-assay coefficient of variation was 5%. 
 
3.10 PCR and RNA preparation 
Tissue segments (20-30 mg) of the corpus were collected from the animals, quickly placed in 
RNA stabilizing reagent (RNA-later, Ambion) and stored at 4° C for 24 h before finally placed 
in -20° C freezer before PCR. The tissue samples were placed in RTL cell lysis buffer (Qiagen, 
Hilden, Germany), homogenized, and total RNA was then extracted using the RNeasy Mini Kit 
(Qiagen). A DNase digestion step (DNase I; Promega, Madison, WI, USA; incubation at 37° C 
for 30 min) was included to remove traces of chromosomal DNA. Samples with A260/ A280 
ratio ≥1.8 were used for PCR. Complementary DNA (cDNA) synthesis was performed using 
oligo dT primers and Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA) on 
1-5 µg of total RNA. 
 
3.11 Quantitative real-time PCR (paper III and IV) 
In paper III real-time qPCR was performed on an ABI 7300 Real-Time PCR System (Applied 
Biosystems, Foster City, CA, USA) using TaqMan gene expression Mastermix (TaqMan®, 
Applied Biosystems Europe BV, Stockholm, Sweden) for ghrelin, gastrin, somatostatin, and 
iNOS, and for the ghrelin receptor, CCK2R and SSTR2. Primers were purchased optimized for 
TaqMan gene expression assay (TaqMan®, Applied Biosystems Europe BV). The expression 
in each reaction was normalized by the expression of hypoxanthine phosphoribosyl transferase 
1 (Hprt1). cDNA exposed to real-time qPCR was performed in 25 µL reaction volumes 
consisting of 20 x TaqMan universal PCR master mix. Amplification was carried out at 50° C 
for 2 min, 95° C for 10 min, 50 cycles of 95° C for 15 sec, and 60° C for 1 min. The absolute 
amounts of transcripts were determined by using several concentrations of standard cDNA 
(1000, 100, 10, and 1 ng) from Wt male SD rats, and qPCR analyses performed in triplicate of 
each sample and standards included in each experiment. 
In paper IV the qPCR was performed on an iCycler iQ real-time detection system (Bio-Rad 
Labs, Hercules, CA, USA) analysing the mRNA expression of TNF, IL-1β and iNOS, and each 
gene normalized to 18S mRNA content. Primers were designed according to previous 
experimentations136, 137 and manufactured by CyberGene® (Stockholm, Sweden). QuantiTect 
SYBR Green PCR Master Mix (Qiagen) was used for the PCR reaction mixture, each sample 
analyzed in triplicate. Melting curves were generated for each reaction to verify the identity of 
amplification product. Thermal cycling conditions: 13 min at 95° C to activate HotStarTaq 
DNA polymerase, followed by 40 cycles at 95° C for 15 s, 60° C for 30 s, and 72° C for 20 s. 
 
3.12 Statistics 
Values are expressed as mean ±SEM or SD; P<0.05 was considered statistically significant. 
The Prism software package 4.0 (GraphPad Software Inc., San Diego, CA, USA) was used for 
the statistical comparisons. 
 
Paper I 
Data obtained with the Bravo capsule was analysed using POLYGRAM NET™ pH software 
(Synmed Medicinteknik, Stockholm, Sweden). Studies with esomeprazole were analyzed as 
changes in pH from baseline at various time points (defined as 0.5 h prior to onset). For fistula 
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studies, the second 30-min collection was used as baseline for comparison with esomeprazole 
and pentagastrin. A Mann-Whitney test followed by a Kruskal-Wallis test was used for changes 
in baseline at the different time-points measured. Bland-Altman analysis was used for 
comparison of variability between the fistula and the Bravo system138. 
 
Paper II 
The Kruskal–Wallis test with Dunn's multiple comparisons post-test was used to evaluate 
differences in acid secretion and peptide concentrations and differences in acid secretion and 
antagonist treatment between the groups. Friedman’s test for paired observations with 
Dunnett’s post-test was used to analyse variations in gut peptide concentrations. 
 
Paper III 
Data obtained with the Bravo capsule was analysed using the POLYGRAM NET ™ pH 
software. Results from YF476 and pentagastrin were analyzed as changes in pH at various time 
points from baseline (defined as 0.5 h prior to onset). The 2(-DeltaDelta C(T)) method was used 
for the qPCR measurements. To compare the data a one-way analysis of variance followed by a 
Dunnett´s multiple comparison test or Mann-Whitney test was used. 
 
Paper IV 
When comparing the MMC cycle length, duration and velocity of activity fronts, and in the fold 
expression changes in the qPCR analysis, the Mann-Whitney test was used. 
. 
  - 17 -  
4 Results 
 
4.1 Paper I 
4.1.1 Comparison between Bravo and fistula methods 
The Bravo system corresponded well with the chronic gastric fistula model as shown by Bland-
Altman analysis. When treated with esomeprazole a rise in pH was seen in the Bravo system 
(pH 2.0 ±0.2 to 3.7 ±0.5) and a decrease in acid output in the fistula model (105 ±21 to 31 ±7 
mmol L-1; P<0.05). Pentagastrin stimulated acid secretion in the fistula model but a 
corresponding change in pH was not seen with the Bravo system. 
 
4.1.2 Basal pH and pentagastrin with the Bravo system 
The mean basal pH levels did not change significantly during fed or fasted conditions over a 
24-h period (2.3 ±0.1 and 2.5 ±0.3, respectively). Neither did infusion of pentagastrin for 6 and 
24 h during fed or fasted states compared to basal pH during saline infusion (fig 9). 
 
 
 
Figure 9. Standard recording with the Bravo system of intragastric pH in a rat during 48 h. The line in the 
top picture shows a basal period of intragastric pH registration for 6 h (8 am–2 pm) and the bottom one 
shows the effect of an infusion of pentagastrin during the same time period. 
 
4.1.3 The effect of esomeprazole on pH and gut hormones 
When given in bolus doses (1, 3, 5 mg kg-1) esomeprazole increased intragastric pH in a dose-
dependent manner (from pH 2.2 ±0.4 to 3.1 ±0.4 compared to baseline, 1.6±0.2) and was 
equally effective during both fed and fasted conditions compared to control (fig 10). Saline, as 
control did not change pH during fed nor fasted conditions.  
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Figure 10. Change from baseline of intragastric pH ±SE after IV bolus of 
esomeprazole (1, 3, 5 mg kg-1) and saline studied for 24 h during 
fed conditions. Mean for all doses vs control and for dose 1 mg kg-1 vs 5 mg kg-1 
(*P < 0.05). 
 
Esomeprazole (3 mg kg-1) markedly elevated intragastric pH from 2.1 ±0.2 to 5.7 ±0.3 (P<0.01) 
during infusion of pentagastrin (90 pmol kg-1min-1) during 24 hours. When given as bolus dose 
esomeprazole 3 mg kg-1 increased the plasma concentrations of ghrelin and somatostatin, while 
gastrin remained stable over the period (P<0.001). 
 
4.1.4 Ghrelin and pH 
When administered IV ghrelin increased intragastric pH from day 1 to day 5 (2.5 ±0.6 to 2.8 
±0.5) compared to control (1.4 ±0.1 to 1.5 ±0.2) during the period (P <0.01). 
 
4.2 Paper II 
4.2.1 Perfusion of the Thiry-Vella loop with saline 
Under control conditions perfusion of the intestinal loop with saline did not change basal gastric 
acid secretion. Pentagastrin stimulation (90 pmol kg-1min-1) increased acid secretion to half-
maximum response (P <0.01), while the luminal peptide content (SOM, NT, and VIP) was 
unchanged. The only gut peptide that changed in plasma under control conditions was 
somatostatin which increased (P <0.05). 
 
4.2.2 The effect of HCl and PEG 
Perfusion of the loops with HCl inhibited pentagastrin-stimulated gastric acid secretion 
significantly more than PEG compared to saline (P <0.01; P <0.06 respectively) (fig 11). 
When challenged with acid the levels of SOM, NT, and VIP in the intestinal perfusate 
increased 1000- (P <0.001), 500- (P <0.05), and 260-fold compared to control. Perfusion 
with PEG gradually increased SOM reaching a maximum with a 3-fold increase over time (P 
<0.01) while NT and VIP did not change. In plasma, when challenged with HCl, only SOM 
increased (P <0.01) while NT and VIP were unchanged. PEG tended to increase SOM (P 
<0.06) as compared to NT and VIP. 
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Figure 11. Luminal challenge of a jejunal Thiry–Vella loop with saline (NaCl, 154 mmol L-1), 
hydrochloric acid (HCl, 50 mmol L-1) and polyethylene glycol (PEG, 800 mOsm L-1). (P < 0.01). 
 
4.2.3 Effect of acid inhibitors on gastric acid secretion 
In this study we examined the effect of the acid inhibitors esomeprazole, ranitidine, and 
gastrazole on acid output with different doses (0.15, 0.3, 1.5, 3, 9, 15 µmol kg-1). At a dose of 
0.3 µmol kg-1 gastrazole inhibited pentagastrin-stimulated acid secretion by 87 ±8% compared 
to esomeprazole 52 ±11%, and ranitidine 47 ±16%. Given at higher doses all acid inhibitors 
reached a similar maximum inhibition (see paper II). 
 
4.3 Paper III 
4.3.1 Intragastric pH and YF476 
Administration of a bolus dose of YF476 (100 mg kg-1 intragastrically; 9 am and 3 pm) during 
continuous pentagastrin stimulation (90 pmol kg-1min-1; 6 h from 9 am to 3 pm and then from 4 
pm to 8 am the following day; repeated for five consecutive days) increased intragastric pH 
compared to basal control conditions during the study period of five days. There were no 
changes of pH between night and day.  
 
4.3.2 YF476, gut regulatory peptides and receptors 
Given as bolus dose (100 mg kg-1 intragastrically) YF476 increased the plasma peptide ghrelin 
and somatostatin 12- and 6-fold, respectively, compared to control (P<0.001), while gastrin 
remain unchanged. There were no changes in gene expression of ghrelin, gastrin or SOM and 
their respective receptors in gastric tissue, except for the GHSR1a which decreased compared to 
the internal control, Hprt1 (p=0.026). 
 
  - 20 -  
4.3.3 YF476 in gastric ulcer prevention  
The gastroprotective ability of YF476 was in the same range as esomeprazole. This was 
reflected by the ulcer index which was reduced in the treatment groups receiving YF476 and 
esomeprazole (4.8 ±2.4 mm; P <0.001; 5.4 ±1.1 mm; P <0.01) compared to controls (70 ±14 
mm).  
The gene expression change of iNOS and gastrin with its corresponding receptor in gastric 
tissue increased 30- (P <0.01), more than 300- (P <0.01) and 18-fold (P <0.05) respectively. 
Ghrelin and somatostatin as well as their receptors did not change. 
 
4.4 Paper IV 
4.4.1 Small bowel motility 
NPS administered IV at different doses (100-4000 pmol kg-1min-1) for 60 min induced irregular 
myoelectric spiking in the lower dose range (100, 300, 1000 pmol kg-1min-1). Higher doses 
(2000 and 4000 pmol kg-1min-1) besides inducing sporadic spiking, also prolonged the MMC 
cycle length and duration of the activity front in a dose-dependent manner. The propagation 
velocity was not changed (fig 12). 
 
Figure 12. Electromyographic recording. Irregular spiking was induced during infusion of NPS at 2000 
pmol kg-1min-1 intravenously (IV) followed by prolongation of the interval between activity fronts. 
 
4.4.2 Expression of TNF, IL-1β, and iNOS 
At 4000 pmol kg-1min-1 NPS induced a 1.8-, 2.9-fold increase in mRNA expression in tissue of 
TNF, IL-1β and iNOS compared to the internal control (18S). 
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5 General Discussion 
We investigated the role of gut peptides on gastric acid secretion and their roles in 
inflammation. 
 
In paper I we developed a novel method of measuring intragastric pH in the rat and compared it 
to a well known standard method, i.e. the chronic fistula. The purpose was to evaluate the 
Bravo system against the fistula method to see whether it was possible to make use of it as a 
supplement to the chronic fistula in an experimental model. We found that the Bravo model 
responded well in comparison to the fistula method and may be better from a physiological 
point of view. Animals restrained in small confinements, as in the chronic fistula, or restrained 
in any way should possibly have a negative influence on the results considering the stress 
imposed on them. The Bravo model allowed the animals to stay in their familiar environment 
during the experiments, and the capsule did not seem to hinder the digestion of food, taking into 
account the weight gained during the period of the trials. In the Bravo model rapid changes in 
pH after treatment of different substances could be registered instantaneously after 
administration which is not the case with the fistula model which relies on infrequent acid 
secretion volumes. On the other hand, the Bravo model is rather expensive, and because of the 
short battery time the experiments must start almost immediately after surgery, which could 
influence the results; even though we did not see any abnormalities in behavior or post mortal 
lesions. Also, the Bravo model does not show any true values of acid output because of the fact 
that it measures only pH intragastrically. This said, the Bravo capsule gave reliable recordings 
during all the experiments and should work as a complement to the chronic fistula model. 
To be able to compare the two methods in experiments we gave pentagastrin which stimulated 
acid output in the fistula, but pH in the Bravo model was unchanged, this could be explained by 
the fact that pH as such is not affected by acid secretion changes. Esomeprazole, used as a 
comparable control of acid inhibition, showed an increased pH and decreased acid output 
accordingly when the two models were compared which gives us an indication of the 
functionality of the new model. When we measured the levels of the gut peptides gastrin, 
ghrelin, and SOM in plasma, gastrin proved to be unchanged in all the trials, which indicates 
that the capsule itself did not distend the stomach. Ghrelin and SOM increased during the 
treatment period. The mechanism behind this is not clear but a synergistic effect between these 
two peptides seems to be at hand 75, 139.  
 
In paper II we examined the inhibitory impact of hydrochloric acid (HCl) and the hyperosmolal 
solution PEG on gastric acid secretion and release of gut peptides SOM, NT, and VIP, in 
addition to inhibitory drugs esomeprazole, ranitidine, and gastrozole. We found that HCl had 
the strongest inhibitory action compared to PEG, which also have been seen in other 
experiments 140, 141. The subsequent release of peptides in the luminal perfusate, and in blood 
weighed in favor of SOM in the perfusate reaching 70 times higher concentrations than in 
blood. Generally, the luminal release dominated over the release to the blood. This implies a 
mechanism in which acid but also hyperosmolal solutions may reach the enteroendocrine cells, 
and even deeper into the mucosa to release peptides such as SOM, NT, and VIP. Considering 
the fact that these peptides influence both neuronal and endocrine pathways there could be a 
dual inhibitor mechanism involving either neuronal or endocrine responses to acid stimulation5, 
142, 143. It is well known that low pH in the stomach affects the SOM-producing D cells to 
release SOM and subsequent inhibition of acid secretion144, 145. In our study we report that this 
phenomenon seems to be true not only for the stomach and duodenum, but also in the smaller 
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intestine. There could be a neuronal extrinsic mechanism involved in the small intestine, but it 
seems to be hidden by the stronger response of SOM to acid as shown in our work.  
In this study we also evaluated the inhibitory effect of esomeprazole, ranitidine, and gastrazole 
on gastric acid secretion. Gastrazole proved to have the strongest inhibitory ability and this 
verifies the importance of gastrin as a key player in regulation of acid secretion from the 
parietal cell, and offers a novel pharmacological tool to study the mechanisms of gastric acid 
secretion. 
 
In paper III we looked into the acid inhibitory effects of the CCK2R antagonist YF476 mediated 
through regulatory peptides. The effects were studied both in animals receiving only YF476 
under pentagastrin stimulation and animals with induced ulcers. Our study showed that YF476 
administered twice daily in male rats during pentagastrin stimulation elevated pH significantly 
without any signs of desensitization of the drug. Further we found that YF476 increased pH to a 
level so as to prevent gastric ulceration by diclofenac in the same range as esomeprazole. 
Therefore YF476 could be expected to enter into treatments of different disorders such as peptic 
ulcer disease and upper gastrointestinal disorders146. In plasma the peptides ghrelin and SOM 
increased significantly compared to gastrin which was unchanged. The fact that somatostatin 
was increased during YF476 administration speaks of a further reduction in gastrin levels from 
the G cells147, 148. The reason for the corresponding increase of ghrelin is not fully explained but 
earlier research has shown this to be true79 and may represent another aspect of regulatory 
mechanisms involved in gastric acid secretion149. 
  
During long-term administration of YF476 the most markedly change in mRNA expression 
was seen for the CCK2R. This could reflect a compensatory effect considering that YF476 have 
their effect on the same receptor. The other receptors did also change but to a lesser extent and 
all to a considerable variability. This variation may be a natural condition in these individuals 
regarding their sensitivity to acid stimulation and regulatory peptides.  
During exposure to NSAID-induced ulceration, an up-regulation of both gastrin and CCK2R 
was seen, alongside the increase in iNOS expression, this may be important in the NSAID-
induced ulcers seen. Reports have shown a subset of COX-2 dependent genes to directly 
influence gastric physiology. During treatment with NSAIDs there is an expression of this 
subset of genes implying a regulation under COX-2 expression150. In addition, gastrin enhances 
the stability and binding of the COX-2 mRNA, and there has been suggested that gastrin also 
activates COX-2 genes in CCK2R containing cells that could further increase COX-2 
expression142, 151. This is in line with our results and as the same genes are present in humans 
there is compelling new link between COX-2 and inflammation. 
 
In paper IV we examined the impact of NPS on small bowel motility and inflammation. NPS 
noticeably provoked a response in the small intestine when administered peripherally with 
irregular spiking and prolonged MMC cycle length. It has been reported that NPS and its 
receptor NPSR1 is involved in different GI functions such as food intake, primarily gastric 
emptying86 and susceptibility to inflammatory bowel disease97. This is implemented in our 
results with irregular spiking and extended MMC cycle length. There is some inconclusive 
evidence of NPS ability to stimulate motility reported by Han et al when administered 
intraperitoneally in doses much higher then ours. He could see no evident results, while there 
was a distinct evocation in motility when administered intracerebroventricularly (IVC)88. This 
pleads for a neurocrine or paracrine effect rather than an endocrine, considering the general 
concept of NPS as a neuropeptide. We also attempted to inquire whether NPS was able to elicit 
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an inflammatory response when administered IV, since it has been linked to inflammatory 
bowel disease. Our investigation showed an increase of TNF and IL-1β, while iNOS decreased. 
Recent discoveries of NPSR antagonists having no effects on basal motility but inhibiting 
exogenous NPS fits with the idea of NPS being associated with inflammation152. Though our 
results could not entirely abide this in terms of cytokines released, the ascertained increase in 
iNOS expression could be of importance since an uninterrupted up-regulation of NO in irritable 
bowel disease is beneficial153, 154. 
 
The inflammatory response of  iNOS, TNF and IL-1β  when subdued to NPS in our study 
increased in expression in the tissue which implies a clinical significance of NPS in mucosal 
healing abilities for conditions such as gastritis155. It is known though that TNF and IL-1β are 
strong inhibitors of gastric acid secretion under a pathophysiological response156, and that 
during the same conditions the inflammatory response of iNOS seems to be an induction of NO 
to maintain the integrity of the gastric epithelium157. Secretion of NPS may possibly play a role 
in this process. The actions of ghrelin, gastrin and somatostatin, and related gut peptides are 
involved in the regulation of the normal physiology, but some also play a part in inflammation 
and control of inflammatory responses, such as ghrelin that seems to have a modulatory impact 
on the course of events during an inflammation158-160. This shows an intricate connection 
between different factors influencing acid secretion and inflammation. 
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6 Summery and Conclusions 
We have shown that gastric acid secretion is regulated by a number of different mechanisms, 
including neurocrine, paracrine, and endocrine pathways. This has been studied in different 
systems and in a newly developed model – The Bravo capsule system – we could conclude that 
prolonged studies of intragastric pH when challenged with acid stimulation (pentagastrin) or 
inhibition (esomeprazole) gave reliable results compared to the standard model of chronic 
fistula in rats, as seen by acid and gut peptide secretion measurements. Furthermore, we could 
support the idea that ghrelin has a stimulatory effect on gastric acid secretion when 
administered IV in rats.  
 
We have also illustrated the effect of luminal exposure to hydrochloric acid and hyperosmolal 
solutions (PEG) on the release of peptides SOM, NT and VIP . Not only in the duodenum but 
also in the small intestine the acid, when released into the lumen triggers a negative feedback 
mechanism which secretes these intestinal peptides. Also PEG stimulates the peptides 
mentioned but to a much lesser extent. It is obvious that acid is the more powerful inhibitor of 
acid secretion in the smaller intestine because of the potential harm it may cause compared to 
the effects of osmolality.  
There was a dominance of SOM release compared to the other peptides, and it was more 
pronounced in the luminal perfusate than in the bloodstream.  
The inhibitory effect of the CCK2R antagonist gastrazole was most potent compared to the 
actions of esomeprazole and ranitidine, which verifies the importance of gastrin for an acid 
response. 
 
The CCK2R antagonist YF476 inhibits gastric acid secretion and promotes mucosal healing. It 
increases gastrin, ghrelin, and SOM levels in plasma, and the mRNA expression of the ghrelin 
receptor in gastric tissue. Treatment with NSAID up-regulates the mRNA expression of gastrin 
and the CCK2R, indicative of a connection between gastrin, CCK2R, and COX-2 in the 
pathogenesis of NSAID-induced gastropathy. 
 
We also studied the effect of NPS administration on intestinal motility and inflammatory 
response. We could conclude that a motility response similar to that in inflammatory reactions 
was seen. Though an early response to NPS did not without exception cause an inflammatory 
reaction, extended activation of the NPS/NPSR system may be involved in inflammatory 
responses of the gut. 
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7 Summary in Swedish 
Utsöndringen av syra i magsäcken är en komplex process som involverar en mängd olika 
mekanismer. Bland annat är ”samtalet” mellan olika peptider en viktig beståndsdel i denna 
process. 
Syftet med avhandlingen var att utveckla en ny metod för att mäta pH i råtta under en längre tid 
och att sedan jämföra denna nya metod med en etablerad. Vi ville studera eventuella 
förändringar i utsöndringen av syra och i MMC-mönstret på råtta vid behandling med olika 
substanser. Till yttermera visso ville vi undersöka eventuella förändringar i genuttryck av olika 
mag-tarmpeptider och inflammationsmarkörer i normal och inflammerad vävnad. 
 
Våra resultat visade att Bravometoden stod sig väl i jämförelse med den etablerade 
fistelmetoden. Vid behandling med esomeprazol (nexium) steg pH-värdet i Bravometoden, 
medan utsöndringen av syra sjönk proportionellt i fistelmetoden. Mag-tarmpeptiderna ghrelin 
och somatostatin ökade i plasma medan gastrin förblev oförändrad vid behandling med 
esomeprazol. Vid behandling med ghrelin ökade pH-värdet liksom också tidigare forskning 
visat. 
 
Peptiderna SOM, NT och VIP ökade både i plasma och tarmperfusatet vid behandling med HCl 
och PEG. Av de tre peptiderna var det SOM som ökade mest i framför allt tarmperfusatet, men 
också i plasma. Gastrazol påvisade den starkast hämmande effekten på utsöndringen av 
magsyra i jämförelse med de två andra syrahämmande preparaten ranitidin och esomeprazol. 
 
YF476, en CCK2-receptorhämmare, blockerade utsöndringen av syra under en längre tid och 
ökade koncentrationerna av ghrelin och somatostatin i plasma. Nivåerna av gastrin förändrades 
emellertid inte under samma tidsperiod. Mängden gastrin, ghrelin och somatostatin i 
magvävnaden varken ökade eller minskade när enbart YF476 gavs och av deras respektive 
receptorer var det bara GHSR1a som förändrades. Vid behandling med NSAID-preparat ökade 
dock uttrycket av gastrin, CCK2-receptorn och iNOS, men ingen av de andra peptiderna och 
deras receptorer. 
 
Behandling med NPS stimulerade till en förändring i MMC-mönstret med oregelbundet 
spikmönster och förlängt avstånd mellan aktivitetsfronterna. Mängden iNOS, TNF, and IL-1β 
ökade också i vävnaden. 
 
Slutsatsen man kan dra är att Bravometoden är tillförlitlig vid mätningar av pH och kan 
användas som ett komplement till fistelmetoden. Regleringen av syrasekretionen tycks inte 
endast begränsad till magen utan verkar också kunna kontrolleras från tunntarmen av framför 
allt somatostatin som frigörs från magsäcken. Olika mekanismer ligger bakom YF476 
syrahämmande förmåga och vid behandling med NSAID-preparat ökar uttrycket av gastrin, 
CCK2-receptorn och iNOS. 
NPS är en tämligen nyupptäckt neuropeptid som tycks påverkar motiliteten i mag-tarmkanalen 
och som kan ha en påverkan på inflammatoriska reaktioner. Detta såg vi en indikation på 
genom att NPS förändrade MMC-mönstret och ökade uttrycket av de inflammatoriska 
markörerna iNOS, TNF, and IL-1β. 
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Abstract
AIM: To evaluate measurements of intragastric pH 
with the Bravo capsule system over a prolonged time. 
METHODS: A Bravo capsule was placed inside the 
rat gastric body and pH was studied for periods up to 
five consecutive days. For comparison, a gastric fistula 
model was used. Effects of ghrelin and esomeprazole, 
with or without pentagastrin, on gastric pH were 
studied. In addition, effects of esomeprazole on plasma 
ghrelin, gastrin and somatostatin were analyzed.
RESULTS: All rats recovered after surgery. The 
average 24-h pH during free feeding was 2.3 ± 0.1 
(n  = 20) with a variation of 18% ± 6% over 5 d. 
Ghrelin, 2400 pmol/kg, t.i.d. increased pH from 1.7 ± 
0.1 to 3.1 ± 0.3 (P  < 0.01) as recorded with the Bravo 
system. After esomeprazole (1 mg/kg, 3 mg/kg and 
5 mg/kg) there was a dose-dependent pH increase 
of maximally 3.4 ± 0.1, with day-to-day variation 
over the entire period of 8% ± 3%. The fistula and 
pH studies generated similar results. Acid inhibition 
with esomeprazole increased plasma ghrelin from 
10 ± 2 pmol/L to 65 ± 26 pmol/L (P  < 0.001), and 
somatostatin from 10 ± 2 pmol/L to 67 ± 18 pmol/L (P  
< 0.001).
CONCLUSION: pH measurements with the Bravo 
capsule are reliable, and comparable to those of the 
gastric fistula model. The Bravo system optimizes 
accurate intragastric pH monitoring over prolonged 
per iods and al lows both short- and long-term 
evaluation of effects of drugs and hormones.
© 2008 The WJG Press. All rights reserved.
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INTRODUCTION
In the past, different techniques have been employed 
to study gastric acid secretion in rodents. The main 
principle for these methods has been collection of  
gastric juice, and in order to measure acid secretion, 
pH titration has been carried out. One of  the earliest 
methods was the pylorus ligation technique[1]. The 
principle of  this method is distension of  the stomach as 
a potent stimulus of  acid secretion. Later, this method 
was altered with an esophageal ligature[2,3], after which 
the stomach of  the rat was removed and secretions 
analyzed. Esophageal ligation in the pylorus-ligated rat 
has been shown to significantly inhibit acid secretion 
by inhibition of  central vagus function[2]. Since then, 
www.wjgnet.com
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the most reliable method has been the chronic fistula 
method[4-6] where a gastric fistula is implanted at the 
greater curvature of  the stomach. This technique 
requires movement restriction of  the animal which is in 
a conscious state during the study. The gastric contents 
are collected and acid output measured. This technique 
allows re-use of  animals following a recovery period 
from the experimental procedure. Other methods used 
today are perfusion of  the gastric lumen[7] and isolated 
perfused, as well as vascularly perfused rat stomach[8-10].
Most of  the above studies have the drawback that 
they do not measure intragastric pH directly and are not 
very physiological, as the animal is either restrained or 
anesthetized. The main goal of  this study was to test 
the feasibility of  a capsule normally used in the clinical 
setting in humans to measure gastroesophageal reflux 
disease (Bravo system) for monitoring intragastric pH 
in the rat. The Bravo capsule system has primarily been 
used in humans[11-14], but also in animals[15] for diagnosis 
of  gastroesophageal reflux disease. 
The aim of  the study was to evaluate the Bravo 
capsule for pH monitoring in the rat. To validate the 
method, we compared the data to those of  the standard 
gastric fistula model.
MATERIALS AND METHODS
Animals
Sprague-Dawley male rats (300-350 g) were purchased 
from Scanbur B&K AB (Sollentuna, Sweden). The rats 
were housed in wire-meshed cages at 24℃ with constant 
humidity and 12:12 h light-dark cycle. The animals were 
fed ad libitum with a commercial rat diet consisting of  
pellet (LABFOR, Lactamin R36, Kimstad, Sweden) and 
tap water prior to the studies. The experiments were 
approved by the Animal Ethics Committee in northern 
Stockholm.
Surgery
Surger y was perfor med under anesthes ia wi th 
pentobarbital sodium (50 mg/kg; Apoteket AB, 
Stockholm, Sweden) intraperitoneally, and Hypnorm 
(fentanyl citrate, 0.315 mg/kg and fluanisone 10 mg/kg; 
Janssen, Oxford, USA) intramuscularly. Marcain 
(bupivacaine hydrochloride, 2.5 mg/kg; AstraZeneca, 
Södertälje, Sweden) was given subcutaneously after 
surgery along the abdominal incision.
For the Bravo system studies, a midline incision was 
performed, and a small opening created in the proximal 
greater curvature, and gastric contents were evacuated. 
An externally pre-calibrated (buffers pH 1.07 and 
7.1) Bravo capsule (an electronic sensor encapsulated 
in PVC-plastic, 25 mm × 5 mm × 5 mm; Synmed 
Medicinteknik AB, Spånga, Sweden) was placed inside 
the stomach with the pH sensor pointing distally and 
anchored with a suture. An indwelling silastic catheter 
(Dow Corning Co., Midland, MI, USA) was inserted into 
the external jugular vein.
For the gastric acid fistula studies, rats were provided 
with a plastic gastric fistula placed immediately proximal 
to the oxyntic gland area near the greater curvature. 
The fistula was closed between experimental periods. A 
silastic catheter was implanted into the external jugular 
vein for drug administration.
Studies of intragastric pH (Bravo system)
Studies of  intragastric pH began in the morning 2 d after 
surgery. The studies were carried out in conscious rats, 
one experiment for each rat, under normal conditions, 
or after a 16-h fasting period in wire-bottom cages with 
free access to water. The animals gained weight (10 ± 3.4 
g during 1 wk) and behaved in a normal fashion, with 
a normal feeding pattern throughout the experiments. 
At post-mortem examination, no mucosal lesions, 
obstruction of  the pylorus or gastric distension were 
seen. Drugs were administered through the external 
jugular vein in all experiments.
The pH recorded by the Bravo capsule was 
transmitted to the Bravo receiver placed directly outside 
the cage. The sampling frequency was 6 Hz. The Bravo 
system was set for a 48-h registration period, after 
which the data were downloaded, batteries replaced and 
recording continued. This procedure was then repeated 
in two more 48-h periods. 
All test compounds were dissolved and diluted 
in isotonic saline solution (sodium chloride, 9 g/L; 
300 mosm/kg H2O, Fresenius Kabi, Halden, Norway).
The effect of  ghrelin on pH: The effect of  ghrelin on 
intragastric pH was studied with ghrelin (2400 pmol/kg) 
given t.i.d (08:00, 12:00 and 16:00) for 5 d in a row (n = 7).
Evaluation of  basal pH: Baseline pH was studied over 
24 h under fed (n = 20) and fasting (n = 8) conditions.
Effect of  esomeprazole on pH: The effect of  
increasing bolus doses of  esomeprazole (AstraZeneca) 
(1 mg/kg, 3 mg/kg or 5 mg/kg iv, n = 10) or saline (iv, 
n = 8) was studied for 24 h in fed rats. Furthermore, the 
effect of  esomeprazole (3 mg/kg iv, n = 10) or saline (iv, 
n = 8) was studied for 24 h in fasting rats. 
The effect of  pentagastrin and esomeprazole on 
pH: The effect of  esomeprazole (3 mg/kg iv, n = 10) 
or saline (iv, n = 8) was studied under pentagastrin 
(NeoMPS, Strasbourg, France) infusion (90 pmol/kg per 
min, iv) over 6 h in both fed and fasting rats. In these 
experiments, the rats were restrained in Bollman cages 
to mimic the gastric fistula studies and for infusion of  
pentagastrin.
The effect of  a 24-h infusion of  pentagastrin (90 
pmol/kg per min iv, n = 6), of  esomeprazole (9 pmol/kg 
per min, n = 6), or saline (0.154 mol/L, n = 6) on pH 
was studied.
Plasma levels of  gut hormones: The effect of  
esomeprazole (3 mg/kg iv) on plasma levels of  ghrelin, 
gastrin and somatostatin was studied. A group of  
animals (n = 10) was divided into two treatment groups 
(each n = 5). All animals were treated with esomeprazole 
daily during 1 wk. The first group of  animals was 
then euthanized, while the other group was followed 
for another week without esomeprazole and then 
euthanaized. Blood was drawn and centrifuged, and 
plasma assayed for concentrations of  ghrelin, gastrin and 
somatostatin. 
For ghrelin measurements, the ghrelin (active) 
radioimmunoassay kit (Linco Research, St. Charles, MI, 
USA) was used, which utilizes 125I-labeled ghrelin and 
ghrelin antiserum to determine the level of  active ghrelin 
in plasma. For the analysis, a Gamma Master 1277 
(LKB-Wallac, Perkin-Elmer Inc, Massachusetts, NH, 
USA) was used. The intra- and interassay coefficients of  
variation were 7% and 14%, respectively.
Somatostat in was analyzed using an EIA kit 
(EK-060-03) from Phoenix Pharmaceuticals, Burlingame, 
CA, USA), which reacts 100% to somatostatin-14 and 
somatostatin-28. The intra- and interassay coefficients 
of  variation were 5% and 14%, respectively. 
Gastrin was analyzed using C-terminal-directed 
CCK/gastrin antiserum 2609/10 (Rehfeld, 1978). 
Chloramine-T-labeled and HPLC-purified gastrin-17 
(NeoMPS) was used as radioligand and gastrin-17 as 
calibrator/standard. The intra- and interassay coefficients 
of  variation were 6% and 8%, respectively.
Studies of gastric acid secretion (fistula)
Studies of  gastric acid secretion began 7 d after surgery. 
The animals gained weight (8 ± 2.6 g during 1 wk) 
and had normal behavior during the experimentation 
periods. Prior to each experiment, food was withheld 
for 18 h, but with free access to water. At the start of  
the experiments, the stomach was rinsed with 10-15 mL 
luke-warm tap water to evacuate remaining food, 
followed by a 30-min period before the experiments 
were started. During the experiments, the conscious rats 
were placed in Bollman cages. Gastric juice was collected 
at 30-min intervals, and volumes measured to the nearest 
0.1 mL. pH was calculated by back-titration using 
0.1 mmol/L sodium hydroxide. Acid output was 
calculated by multiplying the secretion volumes with 
hydrogen ion concentrations and expressed as µmol per 
30-min period.
Baseline acid secretion was studied for 60 min 
followed by esomeprazole (3 mg/kg iv), after which 
acid secretion was studied for another 2 h. During the 
experiment, saline was administered in the same amount 
as collected from the gastric fistula to compensate for 
the volume loss during the experiment. Furthermore, 
baseline acid secretion was studied for 60 min, followed 
by an infusion of  pentagastrin (90 pmol/kg per min) 
for 4 h. After 1 h of  pentagastrin infusion, a bolus of  
esomeprazole (3 mg/kg iv) was administered and acid 
secretion studied for another 3 h.
Data and statistical analysis
The data obtained with the Bravo capsule analyzed 
using (POLYGRAM NET™ pH Testing Application 
software, Synmed Medicinteknik) in 48-h periods. 
Results of  studies with esomeprazole were analyzed by 
calculating changes in pH at various timepoints from 
baseline (defined as 0.5 h prior to onset of  studies). 
For analysis of  the fistula studies, the first 30-min 
collection was discarded and the second collection used 
as baseline for comparison with esomeprazole and 
pentagastrin. 
All data are mean ± SE. A Kruskal-Wallis test 
fol lowed by Mann-Whitney U test was used for 
statistical comparisons using specific time points for 
pH. P < 0.05 was considered statistically significant. For 
comparison of  the variability between the fistula and the 
Bravo system the Bland-Altman analysis was used[16,17]. 
The Prism software package 4.0 (GraphPad Software 
Inc., San Diego, CA, USA) was used for the statistical 
comparisons.
RESULTS
Comparison between the Bravo system and the fistula 
model
Pentagastrin resulted in a marked increase, 83 ± 
9 mmol/L to 132 ± 8 mmol/L (P < 0.05) of  acid 
output in the fistula model, which was not evident as a 
corresponding decrease in pH with the Bravo system. 
During esomeprazole treatment, there was a marked 
increase in pH from 2.0 ± 0.2 to 3.7 ± 0.5, as recorded 
with the Bravo system and correspondingly, a marked 
decrease in acid secretion from 105 ± 21 mmol/L to 31 
± 7 mmol/L in the fistula model (P < 0.05; Figure 1). 
Bland-Altman analysis of  these conditions showed a 
high degree of  agreement between the Bravo system and 
the fistula method as shown in Figure 2.
Evaluation of basal pH
A typical 120-h baseline registration including dose of  
esomeprazole (day 1, 3 and 5) with the Bravo system is 
shown in Figure 3. The feeding status did not alter the 
mean pH over 24 h, but increases in pH were observed 
during afternoon and night-time when animals were fed. 
The mean 24-h pH was 2.3 ± 0.1 during fed conditions 
and 2.5 ± 0.3 during fasted conditions, with 18% ± 6% 
variation during the next four 24-h periods. There was 
no difference in pH between daytime and night-time (1.4 
± 0.1 and 1.7 ± 0.2, respectively).
Figure 1  Change in pH ± SE in the Bravo system and gastric fistula model 
during fasting conditions after iv bolus of esomeprazole (3 mg/kg) and 
pentagastrin infusion (90 pmol/kg per min) for 2 h.
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The effect of bolus esomeprazole on pH
As studied over 24 h, there was a dose-dependent 
increase of  pH after esomeprazole, 1 mg/kg, 3 mg/kg, 
and 5 mg/kg, during free roaming conditions (Figure 4). 
Already 3 h after administration of  esomeprazole, pH 
was significantly higher with 5 mg/kg, 3.1 ± 0.4, than 
with 1 mg/kg, 2.2 ± 0.4 (P < 0.05). Esomeprazole 
(3 mg/kg) increased intragastric pH during saline infusion 
over a 6-h period (2.5 ± 0.2) compared to baseline pH (1.6 
± 0.2), whereas saline did not (P < 0.01; Figure 5A).
Esomeprazole was equally effective during fed or 
fasting conditions (Figure 5A). As a control, saline did 
not change intragastric pH during either fed (baseline pH 
1.4 ± 0.1) or fasting (baseline pH 1.6 ± 0.2) conditions 
(Figure 4, Figure 5A).
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Figure 2  Bland-Altman analysis comparing the Bravo system with the 
fistula method. Mean value -1.7 with 2SD from -3.5 to 0.12.
Figure 5  Changes of intragastric after an iv bolus of esomeprazole. A: 
Change from baseline of intragastric pH ± SE after an iv bolus of esomeprazole 
(3 mg/kg) or saline during fed or fasting conditions for 24 h (aP < 0.05); B: 
Change form baseline of intragastric pH ± SE after an iv bolus of esomeprazole 
(3 mg/kg) or saline during pentagastrin (90 pmol/kg per min) infusion during 
fed or fasting conditions during 6 h. Mean esomeprazole vs esomeprazole 
and pentagastrin for fed (bP < 0.01). Mean esomeprazole fed vs fasting 
esomeprazole and pentagastrin (aP < 0.05). Mean esomeprazole fed vs fasting 
esomeprazole and pentagastrin (bP < 0.01).
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Figure 4  Change from baseline of intragastric pH ± SE after an iv bolus of 
esomeprazole in three different doses and saline studied for 24 h during 
fed conditions. Mean for all doses vs control and for dose 1 mg/kg vs 5 mg/kg 
(aP < 0.05).
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Figure 3  Standard recording with the Bravo system of intragastric pH in a 
rat during 6 d. The solid line indicates bolus doses of esomeprazole (3 mg/kg) 
given iv during 3 min under fed conditions. 
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The effect of pentagastrin on pH
Pentagastrin alone did not change pH over 6 h compared 
with fed (baseline pH 2.1 ± 0.2) or fasting (baseline pH 
2.4 ± 0.2) conditions. After esomeprazole (3 mg/kg), 
pentagastrin infusion markedly decreased pH from 2.0 
± 0.3 to 1.0 ± 0.2 (P < 0.05, Figure 5B). This effect was 
most marked in fed animals.
The effect of 24-h infusion of esomeprazole on pH
After esomeprazole (9 pmol/kg per min) the average 
24-h pH was substantially higher than in the controls, 5.7 
± 0.3 and 2.1 ± 0.2, respectively (P < 0.01). Pentagastrin 
alone did not change pH over the 24-h infusion period 
as compared to saline (Figure 6).
The effect of ghrelin on pH
Administration of  ghrelin, t.i.d markedly increased 
gastric 24-h pH from day 1 (2.5 ± 0.6) to day 5 (2.8 ± 
0.5) compared to control day 1 (1.4 ± 0.1) and day 5 (1.5 
± 0.2) (P < 0.01; n = 7). There was no significant day-
to-day variation of  the ghrelin effect during the five days 
(Figure 7).
Plasma levels of gut hormones
Esomeprazole (3 mg/kg) t.i.d resulted in a marked 
increase in plasma ghrelin and somatostatin concentrations 
as shown in Figure 8 (P < 0.001). Plasma gastrin, however, 
remained stable over the same time period (Figure 8).
DISCUSSION
This study demonstrates that the Bravo system can 
be used for studies of  intragastric pH in rats and that 
the results are comparable to those of  a standard 
fistula model. The system allows for long-term studies 
during unrestrained living conditions. There are several 
advantages with the use of  the Bravo system. Previous 
models for studies of  gastric acid secretion do not allow 
measurements of  pH over a long time. Furthermore, 
during these studies, the animals are kept under stressful 
conditions, which to a certain degree, may influence 
the responsiveness of  the animals to different stimuli. 
The Bravo system uses a telemetric system that records 
gastric pH during 24 h for up to five consecutive days. 
The day-to-day variation was within acceptable limits. 
The system allows for real-time recordings of  intragastric 
pH with the ability to record from the start of  a 
treatment until a detectable effect is seen. The system is 
suitable for long-term studies with continuous infusions 
that are difficult to perform using the fistula model, as 
the animals do not tolerate being restrained in cages 
during prolonged studies. The Bravo recording system is 
also a digital recording system, which means that primary 
data are logged, and permits detailed measurements as 
determined by the set sampling frequency. 
The data are, however, limited to pH-values as no 
secretion volumes are obtained. With the gastric fistula 
model, recordings are made over no less than 15-min 
periods, which can be a limiting factor as regards rapid 
changes in pH, i.e. drug effects. However, in the fistula 
model, secretion volumes are recorded, which permit 
calculation of  a true acid output. The Bravo system has 
a few drawbacks. It is expensive, the battery life of  the 
capsule is short (5 d) and therefore, the animals can only 
be used in studies for about a week. This means that 
experiments must start immediately after the operation 
(in this case 2 d after the surgical procedure), and the 
recovery from surgery may influence the results and 
the comparison with the fistula model. Despite this, the 
Bravo system seems to be well tolerated, as the stomach 
of  the rats did not show any abnormalities or mucosal 
lesions upon autopsy. The animals also gain weight and 
behaved in a normal fashion during the experiments.
From a physiologica l v iew point , our resul ts 
demonstrated expected results; intragastric pH in rodents 
was stable over time, with a slight increase during the 
night during fed conditions.
In addition, treatment with esomeprazole and 
pentagastrin gave expected results. The agreement 
between the Bravo system and the established fistula 
method was evaluated employing a Bland-Altman 
analysis. When the two methods were compared, 
the pH results obtained with the Bravo system were 
comparable to those obtained using the fistula model. 
The differences lie within acceptable limits of  agreement 
approximately 95% of  the time, and the variability 
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Figure 6  Change in mean pH ± SE over time. Mean esomeprazole 
(9 pmol/kg per min) 24 h infusion and pentagastrin (90 pmol/kg per min) 
infusion. (bP < 0.01 vs control).
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Figure 7  Change in mean pH ± SE during treatment with bolus dose 
ghrelin t.i.d. (2400 pmol/kg, bP < 0.01 ghrelin vs control). There was no day-
to-day difference in variation of the ghrelin response during the 5 d.
was consistent across the graph; the scatter around the 
baseline (mean) did not increase with increasing means.
During comparative studies, the animals were 
restrained in Bollman cages for infusion of  pentagastrin, 
so the experimental conditions were the same. During 
esomeprazole treatment, pH rose and gastric acid output 
decreased accordingly. There seemed to be a slight 
delay in response to esomeprazole when studied by the 
fistula method as compared to the Bravo system. The 
reason for this is probably related to the fact that the 
secretory response depends on the physical emptying 
of  gastric contents from the fistula until measurements 
can be done. As judged from our experiments, this 
causes a delay of  the recorded response of  about 
30 min. Pentagastrin increased acid output, but no 
change was seen in intragastric pH with the Bravo 
system. This is explained by the fact that a change in 
secretion volume does not affect the pH recorded, even 
though acid output is changed. The fact that pH does 
not change when introducing pentagastrin may be due to 
the constantly low basal pH level in the rat stomach.
The gut hormones assayed in this study, ghrelin, 
gastrin, and somatostatin, are all found in the mucosa of  
the stomach[18]. They operate in a coherent inhibitory/
stimulatory fashion against one another, i.e. increasing 
levels of  somatostatin stimulates ghrelin, while gastrin 
is inhibited[19,20]. Pentagastrin acts as an agonist on acid 
secretion and has a stimulatory effect on somatostatin, 
which in turn down-regulates the release of  gastrin so 
that excessive amounts of  acid are not produced[20]. The 
fact that basal plasma gastrin levels remained stable with 
the Bravo system indicates that the Bravo capsule by 
itself  does not distend the stomach to such a degree that 
gastrin levels are affected[21].
Our results using the Bravo system, with an increase 
of  intragastric pH during 1 wk after three times daily, 
administration of  ghrelin, are in accordance with earlier 
studies[19,22], but at variance with another[23]. This may 
be explained by the fact that different methods for 
studying gastric acid secretion have been employed, 
some of  which are dependent on gastric motility for the 
emptying of  gastric secretions through the fistula. By 
using the Bravo system, we found no desensitization of  
the pH response to ghrelin. This is at variance with our 
previous studies on intestinal motility, in which a loss of  
the ghrelin response was shown[19,24]. This might be due 
to the fact that motility was stimulated by a continuous 
infusion of  the hormone, whereas the pH effect was 
brought about by repeated injections of  ghrelin, a 
form of  administration that is considered less liable to 
desensitization effects. As ghrelin not only increases 
intragastric pH, but also stimulates gastric emptying 
in rodents[22,23,25,26]. This may be an erroneous factor in 
determining acid secretion using the fistula method.
With esomeprazole treatment, plasma concentrations 
of  ghrelin and somatostatin were increased. This effect 
was maintained for 1 wk after esomeprazole treatment. 
The underlying mechanism for this increase in plasma 
ghrelin and somatostatin is not yet fully understood, but 
may be due to a direct effect of  esomeprazole on ghrelin 
and somatostatin, but also by an indirect effect through 
changes in gastric pH. The counter-balancing effects 
between pentagastrin (low pH) and esomeprazole (high 
pH) as regards ghrelin levels point to a physiological role 
of  ghrelin in the control of  gastric acid secretion[27,28]. 
The rise in somatostatin concentration is likely due to 
a direct effect of  the continuous doses of  ghrelin, as 
pH was not affected. The lack of  elevated levels of  
gastrin for the two groups are probably attributed to the 
increase in somatostatin[29] or, although less likely, low 
doses of  esomeprazole[30,31].
To conclude, the Bravo capsule system is to be used 
for prolonged studies of  gastric pH in free roaming 
conscious rats over days and is well tolerated, and could 
serve as a complement to the gastric fistula model, as 
shown by acid and gut hormone secretion measurements.
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Figure 8  Gut peptide concentrations during treatment week 1 (W1) and week 2 (W2). The two groups of animals (ntot = 10) were treated during one week with 
esomeprazole (3 mg/kg). After the first treatment week the first group (n = 5) were euthanaized and plasma were taken for peptide measurements. The other group (n 
= 5) went on for another week without any drug treatment and then euthanaized and plasma taken for analysis of peptides. aP < 0.05; bP < 0.01; cP < 0.001 vs control. 
 COMMENTS
Background
The pharmacological treatment of gastrointestinal acid-related diseases aims 
at providing ulcer and mucosal healing, symptom relief and improved quality 
of life. Gastric acid inhibitory compounds are widely used in the clinical setting 
in order to treat not only benign gastric and duodenal ulcers, but also gastritis 
and reflux esophagitis. Over the past two decades, there has been a number 
of reports on the use of proton pump inhibitors (PPIs) such as omeprazole and 
the following competitors. The PPIs are activated in the acid environment in 
the stomach and inhibit the final step of gastric acid secretion. They bind in a 
non-competitive way to the H+, K+ -ATPase and inhibit secretion. Even though 
the PPIs have many good properties compared to other treatment regims, 
and are considered the treatment of choice in acid-related gastrointestinal 
diseases, there are drawbacks with PPI treatment. For instance, the onset of 
action is slow as compared to that of H2-receptor antagonists, which induce 
an immediate acid inhibition, and the duration of action may be too short 
giving room for night-time acid breakthrough. So far, treatments have got 
around this problem by recommending a two-dose regimen. Pharmaceutical 
development has been directed against finding a compound with profound acid 
inhibitory action over prolonged periods of time, not permitting night-time acid 
breakthrough to take place. The development of such drugs, however, require 
new methods of studying gastric acid secretion over prolonged periods, up to 
120 h over or more.
Research frontiers
Research concerning acid-related diseases has been focused on PPIs targeted 
against the H+, K+ -ATPase of the stomach and H2-receptor antagonists. Recent 
studies have shown that the proton pump is the most likely candidate for a 
sustainable therapeutic application in the regulation of acid suppression. One 
of the hurdles in this field is the possibility to perform long-term measurements 
of acid secretion in the development of pharmacological treatment of acid 
diseases. Although PPIs are highly effective as a class, differences in their 
pharmacokinetics, such as bioavailability, metabolism, and elimination half-life, 
may translate into differences in clinical outcomes.
Innovations and breakthroughs
Over the latest years, new drugs have emerged on the market, such as being 
PPIs (3rd generation), new potassium channel blocking agents that inhibit gastric 
secretion (P-CAP), and even combinations of PPIs and H2-receptor antagonists. 
A second line to this further development is to be expected and with this new 
method, developed as a tool for evluation of such long-acting drugs, may become 
a feasible tool in the clinical setting for treatment of acid-dependent diseases. 
Applications
Our research demonstrates stable recordings with the Bravo capsule system 
in the rat. The animals were given PPI and ghrelin and this resulted in an 
almost immediate response in pH, sustained during approximately 6 h. The 
capsule model was compared with the fistula model and showed agreement in 
compliance between the two methods. This indicates that the capsule model 
could eventually replace the fistula model. It seems better to use the former 
method because of less strain on the rats, and easier and more gentle handling 
and experimental procedures. Furthermore, the Bravo system set-up is easy to 
manage and the information recorded allows many different analysis variables. 
The system also records over five consecutive days, which previously has not 
been possible in this setting.
Terminology
Bravo capsule system: A catheter-free system used to measure esophageal 
pH (acidity) levels in patients who have or are suspected of having 
gastroesophageal reflux disease, but has now also been used for intragastric 
titration of pH.
Peer review
The measurement of intragastric pH with the Bravo capsule system is 
comparable to that of the gastric fistula model, and is useful for prolonged 
studies of gastric pH, even in free roaming conscious rats over days, as 
described. Although further studies are required, this study indicates the novel 
possibility for investigating the acid and gut hormone secretion under more 
physiological conditions.
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The impact of exposure of the intestinal mucosa to acid and hyperosmolal solutions on the release of the
inhibitory gut peptides somatostatin (SOM), neurotensin (NT) and vasoactive intestinal peptide (VIP) was
studied in conscious rats during pentagastrin-stimulated gastric acid secretion. The animals were equipped
with a chronic gastric ﬁstula to measure acid secretion and a jejunal Thiry–Vella loop for intestinal
challenge with saline, hydrochloric acid (HCl, 200 mmol L−1) or hyperosmolal polyethylene glycol (PEG,
1200 mOsm kg−1). Gut peptide concentrations were measured in intestinal perfusates, and in plasma samples
collected during stimulated acid secretion, and at the end of experiments with luminal challenge of the loops.
After pentagastrin-stimulation acid secretion was dose-dependently inhibited by intravenous administration of
the gastrin receptor antagonist gastrazole, aswell as ranitidine and esomeprazole bymaximally 73±10%; 95±3%;
90±10%, respectively.
Acid perfusion of the Thiry–Vella loop caused a prominent release of SOM both to the lumen (from 7.2±5.0
to 1279±580 pmol L−1) and to the circulation (from 18±5.2 to 51±9.0 pmol L−1) simultaneously with an
inhibition of gastric acid secretion. The release of NTandVIPwasnot affected to the same extent. PEG perfusion of
the loop caused a release of SOM as well as NT and VIP, but less. Simultaneously acid secretion was slightly
decreased.
In conclusion, intestinal perfusion with acid or hyperosmolal solutions mainly releases SOM, which seems to
exert a major inhibitory action in the gut, as shown by inhibition of acid secretion. The other peptides NT and
VIP also participate in this action but to a much lesser degree. The operative pathways of these gut peptides
hence involve both endocrine (SOM) and paracrine actions (SOM, NT, VIP) in order to exert inhibitory functions
on the stomach. The inhibitory action of gastrazole, was in a similar range as that of SOM implying that
physiological acid-induced inhibition of gastric acid may primarily be exerted through inhibition of gastrin
endocrine secretion.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
Luminal acid and hyperosmolal solutions in the proximal small
intestine inhibit gastric acid secretion stimulated by pentagastrin [1–4].
It has been suggested that acid and hyperosmolal solutions act at
different sites along the gut to inhibit gastric acid secretion. Acidiﬁcation
of the jejunum inhibits gastric acid secretion by endocrine, paracrine
and neurocrine mechanisms [5–8]. The underlying mechanisms for the
inhibitory properties of acid and hyperosmolal solutions on gastric acid
secretion have not yet been fully elucidated. Somatostatin (SOM) is
suggested to be amediator of the acid-induced inhibitory processes [8,9]
as SOM reduces both histamine release from enterochromafﬁn-like
(ECL) cells and exerts a direct inhibitory effect on parietal cell function
[10]. Among other gut peptides, neurotensin (NT) in an endocrine
fashion, and vasoactive intestinal peptide (VIP) acting as a neurotrans-
mitter or in a paracrine fashion, are considered to contribute in the
peptidergic interplay of inhibitorymechanisms for gastric acid secretion
[11]. Themechanisms by which NT and VIP inhibit parietal cell function
are unknown. Inhibition of the function of the isolated oxyntic cell
mucosahas not beendemonstrated andno receptors for these inhibitors
are found on parietal cells.
The aim of the present study was to investigate the effects of
luminal acid and hyperosmolal solutions on gastric acid secretion and
the simultaneous release of SOM, NT and VIP to the circulation and to
the intestinal lumen, acting in an endocrine or paracrine fashion to
inhibit gastric acid secretion. Moreover, the effect of a novel gastrin
receptor antagonist gastrazole, was studied and compared with ranit-
idine and esomeprazole.
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2. Materials and methods
All experiments were approved by the local Animal Care Com-
mittee and performed according to the guidelines of theNational Insti-
tute of Health (USA).
2.1. Surgical procedures
The experiments were carried out on 51 male Sprague–Dawley rats
(B&K Universal Ltd, Sollentuna, Sweden) kept under standardized
conditions (room temperature 22 °C, humidity 60%, automatically
regulated 12 h lighting cycles) and were fed ad libitum on a commercial
diet (BK standard feeding, BK). After an overnight fast, the rats were
anesthetized with pentobarbital (50mg kg−1 intraperitoneally, Apoteks-
bolaget, Umeå, Sweden) and operated as described elsewhere [4]. In
short, a 10 cm longThiry–Vella loop of the jejunumwasprepared in each
rat by dividing the duodenum at the pylorus and 6 cm farther distally, at
the ligamentof Treitz. Immediatelydistal to the ligamentof Treitz a 10 cm
long part of jejunumwas removed and a blind loopwas constructed. The
continuous proximal and distal parts of the jejunumwere anastomosed
end-to-end to restore gastrointestinal continuity. The oral end of the
Thiry–Vella loopwas closed, intubatedwith a PE90 catheter (ClayAdams
& Co., Becton Dickinson, Parsippany, NJ, USA), and attached to the
abdominal wall. The distal endwas brought through the abdominal wall
as a mucocutaneous ﬁstula. The catheter was tunnelled subcutaneously
to exit at the back of the animal's neck. Then, a mid-segment of the
duodenal loop, 5–7mm long, with the oriﬁces of the bile and pancreatic
ducts, was implanted end-to-side to the jejunum as a pouch 10 cmdistal
to the entero-anastomosis of the duodenum. To quantify acid secretion
the rats were provided with a plastic gastric cannula placed proximal to
the oxyntic gland area near the greater curvature [12]. The rats had free
access to water 24 h after surgery and access to food on the second
postoperative day. A few days later a siliastic catheter (Dow Corning Co.,
MI, USA) was inserted into the jugular vein for administration saline and
pentagastrin, as well as for blood sampling. The catheters were
pretreated with heparin [13] to avoid clotting in the catheter lumen.
2.2. Experimental procedures
Studies of acid secretion and release of gastrointestinal peptides
began7–10days after surgery. Food, but notwater,waswithheld for 18h
before the experiments were undertaken. Before the start of the
experiments, the rats were placed in Bollman cages to which they
were previously accustomed. Initially, the stomach was rinsed with tap
water. Then, gastric juicewas collected at 30-min intervals of which the
ﬁrst two were discarded, and back-titrated to pH 7.0 (Autoburet,
Copenhagen, Denmark) as described earlier [3,4]. The acid output was
expressed in μmol 30 min−1. Throughout the experiments, which lasted
2.5 h, 0.15 mol L−1 NaCl was initially administrated via the jugular vein
catheter for 120 min at a rate of 2 ml h−1 by an infusion pump (Sage
Instruments, Cambridge, MA, USA). Pentagastrin (NeoMPS S.A., Stras-
bourg, France) at a dose of 90 pmol kg−1 min−1 was added to the
intravenous saline infusion for the remaining 90 min. This dose has
previously been shown to produce maximal acid response in chronic
ﬁstula rats [12]. In control experiments, the intestinal loops were
perfused with 154 mmol L−1 NaCl at a rate of 2 ml h−1 throughout the
experiments as described above. In test experiments, saline was ex-
changed either for HCl (200 mmol L−1; pH 1.1; 380 mOsm kg−1) or for
PEG (1200mOsm kg−1; pH 7.2), whichwas given during 60min starting
from the ﬁfth basal 30-min period and continuing during the whole
pentagastrin infusion period. The concentrations of HCl and PEG were
chosen as they caused maximal inhibition of pentagastrin-stimulated
acid secretion [1,14].
Experiments on the effect of acid inhibitors were carried out in
fasted rats with a gastric ﬁstula. Gastrazole, ranitidine or esomeprazole
were administered IV to conscious rats on top of 90 pmol kg−1 min−1
pentagastrin. The effects of gastrazole (0.15, 0.3, 3 μmol kg−1), ranitidine
(0.15, 0.3, 3 μmol kg−1) and esomeprazole (0.15, 3, 9, 15 μmol kg−1)
administrationwere examined. Acid output was expressed as μmol [H+]
per 30-min period. Experiments were carried out using individual
animals exposed to both pentagastrin and antagonist treatments.
2.3. Extraction of samples and radioimmunoassay
During the experiments, perfusates from the loops were collected
on ice during each 30-min period for analysis of gut peptide
concentrations. Blood samples withdrawn from the jugular vein
catheter for the same purpose were obtained at the end of the fourth
basal period as well as at the end of the experiments. However, in
control experiments blood samples were collected only at the end of
experiments. The blood samples were centrifuged at 4 °C, pipetted off
and plasma collected. All samples were stored at −80 °C until ex-
traction procedures and radioimmunoassay (RIA). The peptides were
then absorbed onto and eluted from Sep Pak C18 cartridges (Waters,
Millipore Co., Milford, MA, USA). Elute A consisted of 0.1% triﬂuor-
oacetic acid, 0.06 mol L−1 NaCl and 99.9% water. Elute B consisted of
0.1% triﬂuoroacetic acid, 19.9% water, 0.06 mol L−1 NaCl and 80%
methanol. Samples were then evaporated to dryness at 45 °C under
nitrogen gas before dissolution and RIA.
SOM-like immunoreactivity (LI) was analyzed as described earlier
[15]. The detection limit was 2 pmol L−1, and the intra- and interassay
coefﬁcients of variation were 7% and 11% respectively.
NT-LI was analyzed using antiserum H which reacts with NT, NT
(4–13) (118%), NT(8–13) (167%) and NT(9–13) (15%), but not with
N-terminal fragments of NT. The detection limit of the assaywas 8 pmol
L−1, and the intra- and interassaycoefﬁcientof variationwere 8%and13%
respectively [16].
VIP-LI was analyzed in plasma and perfusates using antiserum VIP2
raised against conjugated natural porcine VIP. The antiserum does not
cross-react with gastrin, pancreatic polypeptide, glucagon, neuropep-
tide Y or NT. The detection limit of the assay was 3 pmol L−1. Intra- and
interassay coefﬁcient of variation were 9% and 13% respectively.
2.4. Statistics
The results are presented as means±SEM. Differences in acid se-
cretion and peptide concentrations and differences in acid secretion
and antagonist between the groups were evaluated using the Kruskal–
Wallis test with Dunn's multiple comparisons post-test. Variations in
gut peptide concentrations were evaluated using the Friedman test for
paired observations with Dunnett's post-test. Pb0.05 was considered
signiﬁcant.
Fig. 1. Change of gastric acid output during basal and pentagastrin-stimulated gastric
acid secretion during luminal challenge of a jejunal Thiry–Vella loop with saline (NaCl),
hydrochloric acid (HCl) and polyethylene glycol (PEG). ⁎⁎pb0.01.
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3. Results
3.1. Control conditions
Under control conditions with saline perfusion of the intestinal
loop there was a stable basal acid secretion. Upon stimulation with
pentagastrin 90 pmol kg−1 min−1 acid secretion increased to maximal
levels (pb0.01), whereas the luminal concentrations of SOM, NT and
VIP did not change (Fig. 2A). In plasma, the circulating levels of SOM
increased (pb0.05) after introduction of pentagastrin, but the levels of
VIP and NT did not change (Fig. 3).
3.2. Challenge with hydrochloric acid
Perfusion of the intestinal loop with HCl reduced the pentagastrin-
stimulated gastric acid secretion compared to control (pb0.01) (Fig. 1).
With a delay of 30minwe found amarked release of the levels of SOM
in the intestinal perfusate increased 1000-fold (pb0.001), similar to
NT and VIP which increased 500- (pb0.05) and 260-fold (pb0.05),
respectively (Fig. 2B). The increase of gut peptide release displayed no
signiﬁcant differences between SOM, NT and VIP, neither as regards
concentrations or time proﬁle.
At the same time the circulating levels of SOM in plasma increased
markedly (pb0.01) compared to VIP and NT, which were unchanged.
In comparisonwith exposures of the Thiry–Vella loop to NaCl and PEG,
the plasma increase of somatostatin in response to HCl was markedly
increased (pb0.001) (Fig. 3).
3.3. Challenge with hyperosmolal polyethylene glycol
Perfusion of the intestinal loop with hyperosmolal PEG tended to
lower the gastric acid output compared to control (pb0.06) (Fig. 1).
Concomitantly, the levels of SOM in the luminal perfusate gradually
increased over time reaching maximum with a 3-fold increment
(pb0.01). This was signiﬁcantly more outspoken (pb0.01) than for NT
and VIP, which did not change (Fig. 2C). The plasma levels of SOM in
plasma tended to increase (pb0.06) as compared to VIP andNT (Fig. 3).
3.4. Pharmacological acid inhibitors
Intravenous administration of an acid inhibitor (gastrazole, raniti-
dineand esomeprazole; eachn=6) produceddose-dependent inhibition
of pentagastrin-stimulated gastric acid secretion (Fig. 4). Gastrazolewas
the most potent when given at a dose of 0.3 μmol kg−1 (87±8%) com-
pared to ranitidine at the same dose (47±16%) and esomeprazole (52±
11%). At higher dosages all three drugs reached a similar maximal
inhibition of 73±10%, 95±3% and, 90±10% for gastrazole, ranitidine and
esomeprazole, respectively.
4. Discussion
Peptidergic regulatory mechanisms play important roles in the
inhibition of gastric acid secretion [17–22]. Long experience has shown
that inhibition of acid secretion is mainly sensitive to low pH as well as
high osmolality [1–4,23,24]. We have therefore chosen to study the
inhibitoryaction of twodifferent stimuli representative for physiological
conditions, namely 200 mM hydrochloric acid and 1200 mOsm
polyethylene glycol. We found that acid caused the most marked
inhibition of acid secretion, while hyperosmolality not quite signiﬁ-
cantly decreased acid secretion during the 120-min period studied [14].
During this period, however, gross changes in gut peptide release were
observed [23]. Two ways of output were analysed; secretion to the
lumen and to the bloodstream. Broadly speaking the luminal release
outweighed the release to the bloodstream. This was most evident for
SOM where the luminal concentrations reached levels about 70 times
higher than thosemeasured in the circulation. Even forNTand VIP there
was a pronounced increase to the lumen which was shown for the
bloodstream [25]. Our data suggest that mainly acid, but also hy-
perosmolal solutions, may reach the enteroendocrine cells to stimulate
the release of gut peptides, such as SOMandNT. In addition it seems that
acid may penetrate even deeper into the mucosa in order to inﬂuence
the release of neuropeptides from neuronal tissues. This opens the
possibility that acid may stimulate dual inhibitory mechanisms
mediated either through endocrine and neuronal mechanisms or
depending on the circumstances that one pathway may suppress or
dominate over the other [26].
It is well known that SOM-containing D-cells of the antrum are
sensitive to low pH and upon stimulation release their peptide in order
to reduce acid secretion as a balancing physiological feedback to
counteract a deleterious effect of acid [20,26,11]. As shown in this study
this also seems to go for the small intestine as an isolated Thiry–Vella
loop of the jejunum was capable of inhibiting gastric acid secretion.
Fig. 3. Plasmaconcentrationsof somatostatin, neurotensin andvasoactive intestinal peptide
during basal (60 min) and after challenge of a jejunal Thiry–Vella loop with saline (NaCl),
hydrochloric acid (HCl) and polyethylene glycol (PEG) (120 min). ⁎pb0.05, ⁎⁎pb0.01.
Fig. 4. Dose–response inhibition of acid secretion 30 min after intravenous adminis-
tration of gastrozole, ranitidine or esomeprazole.
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Thus, a SOM-mediated endocrinological acid inhibitory mechanism
seems to be valid not only for the antrum and duodenum [27], but also
for the greater part of the small intestine.Whether the origin of the SOM
is intestinal or released fromthe gastricmucosabyanother secretagogue
from the small intestine is not yet conﬁrmed. The possibility of a
supplementary neuronal acid inhibitory mechanism is most likely to be
due to direct stimulation of local nerve plexuses in the gutwall. Extrinsic
pathways may be involved but to a lesser extent andmay bemasked by
the seemingly stronger endocrine response to HCl in the small intestine
with SOM and CCK as the main acid inhibitors [8].
Esomeprazole, ranitidine and gastrazole inhibits gastric acid se-
cretion through different cellular mechanisms. Ranitidine is a potent
H2-receptor blocker [28], while gastrazole inhibits gastric acid se-
cretion through the CCK-2 receptor [29,30]. According to our present
results gastrazole seems to be more potent than ranitidine and
esomeprazole to inhibit acid secretion. The temporally prompt effect
of gastrazole veriﬁes the importance of gastrin for acid secretion from
the parietal cell, and offers a new principle for pharmacological
studies of acid secretion, namely inhibition of endocrine gastrin stim-
ulation of the parietal cell.
When acid is released into the lumen of the duodenum, and also
further into the small intestine this signal seems to trigger a negative
feedbackmechanismwhich releases different intestinal peptides [8,2].
Acid seems to be more powerful in activating inhibitory mechanisms
with release of intestinal peptides in the small intestine than hy-
perosmolal solutions. Primarily SOM contributes to inhibition of
gastric acid secretion which seems valid for both acid and hyper-
osmolal solutions in the gut [1,2]. The reason for this is obvious, as acid
is a far more powerful aggressor fromwhich the intestinal mucosa has
to be protected than the effects of osmolality.
Acknowledgement
We thank Wiveca Ring-Persson at Gustav V Research Institute for
the great technical support and assistance.
References
[1] Mogard M, Emås S, Nylander G, Wallin B, Wallin C. Inhibition of pentagastrin-
stimulated gastric acid secretion by upper intestinal hyperosmolality in chronic
gastric ﬁstula rats. Digestion 1982;24:183–9.
[2] Wallin C, Emås S, Nylander G. Acid and hyperosmolal solutions in the upper
intestine of chronic gastric ﬁstula rats inhibit gastric acid secretion by different
mechanisms. Scand J Gastroenterol 1985;20:1083–90.
[3] Wallin C, Nylander G, Emås S. Acid in proximal and distal duodenum inhibits, but
hyperosmolal solution does not inhibit pentagastrin-stimulated acid secretion in
chronic gastric ﬁstula rats. Acta Physiol Scand 1988;132:577–81.
[4] Wallin C, Emås S. Duodenal acidiﬁcation and jejunal hyperosmolality inhibit
pentagastrin-stimulated acid secretion in chronic gastric ﬁstula rats. Scand J Gastro-
enterol 1989;24:1095–101.
[5] Andersson S. Inhibitory effects of acid in the antrum-duodenum on fasting gastric
secretion in Pavlov and Heidenhain pouch dogs. Acta Physiol Scand 1960;49:42–56.
[6] Wormsley KG, Grossman MI. Inhibition of gastric acid secretion by secretion and
by endogenous acid in the duodenum. Gastroenterology 1964;47:72–81.
[7] Konturek S, Grossman MI. Effect of perfusion of intestinal loops with acid, fat, or
dextrose on gastric secretion. Gastroenterology 1965;49:481–9.
[8] Orloff SL, Bunnett NW, Walsh JH, Debas HT. Intestinal acid inhibits gastric acid
secretion by neural and hormonal mechanisms in rats. Am J Physiol 1992;262:
G165–170.
[9] Orloff SL, Bunnett NW, Wong H, Walsh JH, Debas HT. Neural and hormonal
mechanisms mediate the enterogastric reﬂex: a study in intestinal transplants in
rats. Gastroenterology 1991;101:734–42.
[10] Nylander O, Bergqvist E, Öbrink KJ. Dual inhibitory actions of somatostatin on
isolated gastric glands. Acta Physiol Scand 1985;125:111–9.
[11] Schubert ML, Shamburek RD. Control of acid secretion. Gastroenterol Clin North
Am 1990;19:1–25.
[12] Emås S, Nylander G, Wallin B. Comparison of the dose–response curves for acid
output to pentagastrin determinated by two techniques in chronic gastric ﬁstula
rats. Digestion 1981;22:94–100.
[13] Larm O, Larsson R, Olson P. A new thrombogenic surface prepared by selective
covalent binding of heparin via a modiﬁed reducing terminal residue. Biomater
Med Dev Artif Organs 1983;11:2–3.
[14] Emås S, Nylander G, Wallin B, Wallin C. Inhibition of pentagastrin-stimulated
gastric acid secretion by acid perfusion of the duodenum in chronic gastric ﬁstula
rats. Scand J Gastroenterol 1983;18:685–90.
[15] Grill C, Gutniak M, Roovete A, Efendic S. A stimulating effect of glucose on
somatostatin release is impaired in noninsulin-dependent diabetes mellitus. J Clin
Endocrinol Metab 1984;59:293–7.
[16] Theodorsson-Norheim E, Rosell S. Characterization of human plasma neurotensin-
like immunoreactivity after fat ingestion. Regul Pept 1983;6:207–18.
[17] Tebbe JJ, Mronga S, Schäfer MK, Rüter J, Kobelt P, Mönnikes H. Stimulation of
neurons in rat ARC inhibits gastric acid secretion via hypothalamic CRF1/2- and
NPY-Y1 receptors. Am J Physiol 2003;285:G1075–1083.
[18] García-Zaragozá E, Hernández C, Barrachina MD, Esplugues JV. Interleukin 1 beta-
induced inhibition of gastric acid secretion involves glutamate, NO and cGMP
synthesis in the brain. Naunyn-Schmiedeberg's Arch Pharmacol 2003;367:22–7.
[19] Geoghegan JG, Pappas TN. Central peptidergic control of gastric acid secretion. Gut
1997;40:164–6.
[20] ElMunshid HA, Håkanson R, Liedberg G, Sundler F. Effects of various gastrointestinal
peptides on parietal cells and endocrine cells in the oxyntic mucosa of rat stomach.
J Physiol (Lond) 1980;305:249–65.
[21] Ben-Hamida A, ManWK, Spencer J. The effect of some gastrointestinal peptides on
pentagastrin-stimulated acid secretion and oxyntic mucosal histamine in rats.
Inﬂamm Res 1996;45:S46–47.
[22] Grupcev G, Wallin C, Emås S, Theodorsson E, Hellström PM. Transforming growth
factor-α and epidermal growth factor inhibit gastric acid secretion and stimulate
releaseof somatostatin andneurotensin in the conscious rat. Regul Pept1994;52:111–8.
[23] Wallin C, Grupcev G, Emås S, Theodorsson E, Hellström PM. Release of so-
matostatin, neurotensin and vasoactive intestinal peptide upon inhibition of gas-
tric acid secretion by duodenal acid and hyperosmolal solutions in the conscious
rat. Acta Physiol Scand 1995;154:193–203.
[24] Emås S, Håkanson R. Intraduodenal instillation of acid and hyperosmolal solution
suppresses pentagastrin-stimulated acid secretion but not histamine mobilization
in the rat stomach. Scand J Gastroenterol 1987;22:776–80.
[25] LuceyMR,Wass JA, Fairclough PD, O'HareM, Kwasowski P, Penman E,Webb J, Rees
LH. Does gastric acid release plasma somatostatin in man? Gut 1984;25:1217–20.
[26] Chen D, Friis-Hansen L, Håkanson R, Zhao CM. Genetic dissection of the signaling
pathways that control gastric acid secretion. Inﬂammopharmacology 2005;13:201–7.
[27] Ferri GL, Adrian TE, Soimero L, Blank M, Cavalli D, Biliotti G, Polak JM, Bloom SR.
Intramural distribution of immunoreactive vasoactive intestinal polypeptide (VIP),
substance P, somatostatin and mammalian bombesin in the oesophago-gastro-
pyloric region of the human gut. Cell Tissue Res 1989;256:191–7.
[28] Berner BD, Conner CS, Sawyer DR, Siepler JK. Ranitidine: a new H2-receptor
antagonist. Clin Pharm 1982;1:499–509.
[29] Chau I, Cunningham D, Russell C, Norman AR, Kurzawinski T, Harper P, Harrison P,
Middleton G, Daniels F, Hickish T, Prendeville J, Ross PJ, Theis B, Hull R, Walker M,
ShankleyN, KalindjianB,MurrayG, Gillbanks A, Black J. Gastrazole (JB95008), a novel
CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer:
results from two randomised controlled trials. Br J Cancer 2006;94:1107–15.
[30] Buck IM, Black JW, Cooke T, Dunstone DJ, Gaffen JD, Grifﬁn EP, Harper EA, Hull RA,
Kalindjian SB, Lilley EJ, Linney ID, Low CM, McDonald IM, Pether MJ, Roberts SP,
Shankley NP, Shaxted ME, Steel KI, Sykes DA, Tozer MJ, et al. Optimization of the in
vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as
potent cholecystokinin-2 (CCK2) antagonists. J Med Chem 2005;48:6803–12.
12 T. Rudholm et al. / Regulatory Peptides 152 (2009) 8–12

III

Manuscript Rudholm 1 
 
CCK2-receptor antagonist YF476 prevents NSAID-induced 
gastric ulceration through acid inhibition mediated by regulatory 
peptides  
 
T. RUDHOLM1, L. GILLBERG1, E. THEODORSSON2, G. SANGER3, C.A. CAMPBELL3, 
M. BOYCE4, E. NÄSLUND5, P.M. HELLSTRÖM6 
 
1Departments of Medicine, Gastroenterology and Hepatology unit, Karolinska Institutet, 
Karolinska University Hospital, Solna, 2Clinical Chemistry, Linköping University, Linköping, 
Sweden, 3Neurology and GI CEDD, GlaxoSmithKline, Harlow, UK, 4Hammersmith 
Medicines Research, London, UK and 5Clinical Sciences, Karolinska Institutet, Danderyd 
Hospital, Stockholm, and 6Medical Sciences, Gastro unit, Uppsala University, Uppsala, 
Sweden 
 
Short title: CCK2-receptor antagonist prevents NSAID ulcers 
 
Correspondence: Per M. Hellström, MD, PhD 
  Dept of Medical Sciences, Gastro unit 
University Hospital 
SE-751 85 Uppsala, Sweden 
Phone: +46 18 6114285  
Fax:     +46 18 515998 
  E-mail: Per.Hellstrom@medsci.uu.se
Manuscript Rudholm 2 
Abstract 
 
Aim: Study effects of the CCK2-receptor antagonist YF476 on gastric pH, plasma peptide 
levels, gene expression of peptides and receptors for prevention of NSAID ulcerations in rats. 
Method: A Bravo capsule inside the stomach measured pH for five consecutive days. Gastric 
and jugular vein catheters were implanted for blood sampling, and administration of drugs. 
Plasma and gastric tissue was analysed for gastrin, ghrelin, somatostatin, their receptors and 
inducible nitric oxide synthase (iNOS) using immunoassays and quantitative real-time PCR. 
Results: Gastric pH recorded over 24 hours was 2.3±0.6 in controls; variation 19±4 % over 
study days. With YF476, gastric pH rose to 3.5±0.3 (P<0.001). Ulcer index showed 
gastroprotective effects of YF476 and esomeprazole against diclofenac-induced gastric ulcers 
compared to control (4.8±2.4, P<0.001; 5.4±1.1, P<0.01; control 70±14 mm). After YF476 
treatment, plasma ghrelin and somatostatin increased 12- and 6-fold, respectively (P<0.001), 
whereas gastrin was unchanged. Gene expression of gastrin, ghrelin, somatostatin and the 
receptors CCK2 and SSTR2 in stomach did not change after YF476 except ghrelin receptor, 
which decreased compared to internal control (p=0.026). Diclofenac induced 30-fold 
expression of gastric iNOS (P<0.001), 300-fold expression of gastrin (P<0.01), and nearly 20-
fold of CCK2-receptor (P<0.05). Ghrelin, somatostatin and their receptors were unchanged. 
Conclusion: The CCK2-receptor antagonist YF476 increased gastric pH without concomitant 
hypergastrinemia. Other stomach peptides, ghrelin and somatostatin, increased in circulation 
while their tissue content and receptors were unaffected except ghrelin receptor which 
increased. Thus, YF476 may prevent NSAID ulcerations by inhibition of acid secretion 
involving somatostatin and over-expressed gastrin and CCK2-receptor. 
 
Key words: Diclofenac, gastric acid, gut hormones, nitric oxide synthase, pH.
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Introduction 
 
The acid-producing oxyntic part of the rat stomach is rich in endocrine and paracrine cells, 
including enterochromaffin-like (ECL)-cells containing histamine1, G-cells localised to the 
antrum2 A-like or Gr cells holding ghrelin and obestatin3, and D-cells with somatostatin4. An 
important part of the acid secretion process is the stimulation and release of gastrin and the 
subsequent activation of its receptor, the cholecystokinin-2 (CCK2) receptor, located on the 
histamine producing ECL-cells5. Among other important physiological regulators of gastric 
acid secretion somatostatin is a potent inhibitor of gastric acid secretion6, and ghrelin which 
seems to stimulate acid secretion probably through dual actions mediated by the vagus nerve 
and histamine7-9. 
The standard treatment in management of gastroesophageal reflux (GERD), and peptic ulcer 
disease is proton pump inhibitors (PPIs) which cause a remarkable suppression of acid 
secretion by inhibiting the final common step in the proton pump10, 11. Although PPIs seem to 
be the most effective therapy one problem with this treatment is the hypergastrinemia with 
rebound acid hypersecretion resulting in acid-related symptoms once PPI therapy is 
withdrawn12-15. Another problem is the loss of durability of acid suppression during the night 
or early morning when massive acid secretion takes place10. This nocturnal acid breakthrough 
is defined as the presence of intragastric pH < 4 during the overnight period for at least 60 
continuous minutes in patients taking PPIs. Nocturnal acid breakthrough occurs in a sizeable 
part of patients on PPI therapy and has clinical consequences in particular in patients with 
complicated GERD16.  
The search for more physiologically adapted compounds for optimal therapy is under 
continuous development. Considering gastrin as the main stimulant of food-induced acid 
secretion, different approaches have been made to deal with acid-related diseases by 
inhibition of this pathway. YF476, a CCK2-receptor antagonist, structurally related to 
benzodiazepine derivatives, has recently received clinical interest17, 18. The rationale of using 
a CCK2-receptor antagonist in preventing acid secretory disorders is based on the drugs ability 
to counteract the hypergastrinemia that occurs under PPI treatment. Furthermore, in patients 
with extended PPI treatment who still experience acid-related symptoms due to 
hypergastrinemia a CCK2-receptor antagonist would be the drug of choice19,20.  
The primary aim of this study was to investigate the effect of YF476 on gastric long-term pH 
and its healing properties on non-steroidal anti-inflammatory drug (NSAID)-induced gastric 
ulcerations. In addition, as a secondary aim, the plasma levels of the regulatory peptides 
gastrin, ghrelin and somatostatin produced by endocrine cells in the stomach were studied. 
Furthermore, tissue gene expression of gastrin, ghrelin and somatostatin and their respective 
receptors; CCK2-receptor, ghrelin receptor and somatostatin receptor-2 (SSTR2) were 
investigated, using real-time quantitative PCR (qPCR) in normal and in NSAID-induced 
gastric ulcerations using the expression of inducible nitric oxide synthase (iNOS) as a marker 
of inflammatory activity.  
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Material and Methods 
 
Chemicals  
YF476, (R)-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyri-dyl)-1H-1, 4-benzo-diazepin-3-
yl]-3-(3-methylaminophenyl)urea, was generously supplied by Malcolm Boyce 
(Hammersmith Medicines Research, London, UK).  
 
Animals 
Sprague-Dawley male rats (300-350 g) were purchased from Scanbur B&K AB (Sollentuna, 
Sweden). The animals were fed ad libitum with a commercial rat pellet diet (LABFOR, 
Lactamin R36, Kimstad, Sweden) and tap water. At least 7 days prior to the experiments rats 
were allowed to adapt to the environment in housed in wire-meshed cages at 24° C with 
constant humidity and 12:12 hour light-dark cycle. During recovery after surgery, the rats 
were daily trained to accept experimental conditions. Experiments were then carried out in 
conscious animals after a fasting period, at most 15 hours, in wire-bottomed cages with free 
access to water. The experiments were approved by the Animal Ethics Committee in northern 
Stockholm. 
 
Surgical procedures 
Surgery was performed under anesthesia with a mixture of midazolam (5 mg mL-1, 
Midazolam Aktavis AB, Stockholm, Sweden) and Hypnorm (fentanylcitrate, 0.315 mg kg-1 
plus fluanisone 10 mg kg-1; Janssen-Cilag, Sollentuna, Sweden) given subcutaneously (SC) at 
a dose of 1.5-2 mL kg-1 body weight. Buprenorfin (Temgesic® 0.3 mg mL-1, Schering-
Plough, Stockholm, Sweden) 0.05 mg kg-1 body weight was given SC after surgery to relieve 
post-operative pain. 
 
A Bravo capsule (an electronic pH sensor encapsulated in PVC-plastic, 25x5x5 mm; Synmed 
Medicinteknik AB, Spånga, Sweden) was surgically placed inside the stomach as previously 
described21. In brief, a midline incision was done, creating a small opening in the proximal 
greater curvature and gastric contents evacuated. Then, the capsule was sutured to the mucus 
layer of the stomach with the pH sensor pointing distally. An indwelling silastic catheter 
(Dow Corning Co., Midland, MI, USA) pretreated with heparin22 was inserted into the 
external jugular vein in all animals, except those given gavage, for administration of saline 
and pentagastrin, as well as for blood sampling. Finally, a catheter (Dow Corning Co.) 
provided with a small flange was anchored in the fundus part of the stomach near the lesser 
curvature. The catheters were then tunneled at the back of the animal’s neck and the opening 
soldered with heat to prevent leakage of gastric contents. 
 
Experimental procedures 
Studies of intragastric pH. Experiments were carried out in conscious rats (n=12) and began 
in the morning two days after surgery. The studies were carried out as one experiment in each 
rat. The animals gained weight (8.0 ±4.1 g) and behaved in a normal manner with normal 
feeding pattern throughout the experiments. At post-mortem examination, no mucosal lesions, 
obstruction of the pylorus or gastric distension were seen. YF476 was administered as a 
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suspended solution (100 mg kg-1 body weight dissolved in 0.5% methyl cellulose) through the 
gastric catheter in all experiments twice daily (8 am and 5 pm). 
The pH recorded by the Bravo capsule was transmitted with sampling frequency 6 Hz to the 
Bravo receiver placed immediately outside the cage. The Bravo system was set for a 48-h 
recording period after which data was downloaded, batteries replaced and recording 
continued. This procedure was then repeated for two more periods up to 120 hours.  
 
Studies on stomach regulatory peptides and receptors. The effect of YF476 on the plasma 
concentrations of regulatory peptides and gastric pH was studied with bolus dose of YF476 
(100 mg kg-1 body weight) given intragastrically twice daily (9 am and 4 pm) during 
stimulation of acid secretion with pentagastrin 90 pmol kg-1min-1 IV for 6 h (9 am to 3 pm) 
and then for 16 h (4 pm to 8 am) repeated for five consecutive days. A sample of 200 µL 
blood was drawn twice during the experiment, 1.5 h after each administration of YF476, 
centrifuged at 3000 rpm for 10 min and 100 µL of plasma collected and stored as aliquots in -
20° C freezer for subsequent analysis of regulatory peptides. 
 
Studies on NSAID-induced gastric ulcers. The animals (n=24) were deprived of food but had 
free access to water 18-20 h before induction of gastric ulcerations with diclofenac. The rats 
were then given a single dose of either saline solution (sodium chloride 9 g L-1, Fresenius 
Kabi, Halden, Norway), esomeprazole (140 mg kg-1; esomeprazole (Nexium 40 mg, 
AstraZeneca, Södertälje, Sweden) or YF476 (100 mg kg-1 dissolved in 0.5% methyl cellulose) 
one hour prior to the administration of diclofenac (Voltaren® 25 mg mL-1, Novartis, Basle, 
Switzerland) 30 mg kg−1, via gavage and left in their cages for 4 hours after the final dose. 
The animals were then sedated with CO2 and euthanized by cervical dislocation. The 
abdomen was opened, the stomach removed and gently washed in phosphate buffered saline 
and pinned open for photographic documentation (Fig. 1). The ulcer index23 (expressed as 
mm) reflects the total length of gastric lesions per stomach as judged by three independent 
researchers blinded to the protocol. 
 
Tissue sampling and RNA isolation 
At the end of experiments the animals (n=12 for the pH study; n=24 for the diclofenac study) 
were euthanized with an overdose pentobarbital sodium (Apoteksbolaget, Solna, Sweden) or 
sedated with CO2 and euthanized by means of cervical dislocation. Tissue segments (20-30 
mg) of the corpus of the stomach were collected from each animal, quickly placed in RNA-
stabilizing reagent (RNAlater, Qiagen, Hilden, Germany) and stored at 4° C for 24 h before 
finally placed in -20° C freezer before qPCR analysis. 
For RNA extraction tissue samples were placed in RTL cell lysis buffer (Qiagen, Hilden, 
Germany) and homogenized by means of a rotor-stator knife (Ultra-Turrax T8, IKA®-Werke, 
Staufen, Germany). Total RNA was then extracted using the RNeasy Mini Kit according to 
the manufacturer’s instruction (Qiagen). Finally, a DNase digestion step (DNase I; Promega, 
Madison, WI, USA) with incubation at 37° C for 30 min was included to remove traces of 
chromosomal DNA. 
 
Samples with A260/ A280 ratio ≥1.8 were used for qPCR. Complementary DNA (cDNA) 
synthesis was performed on 1-5 µg of total RNA using oligo dT primers and Superscript III 
reverse transcriptase (Invitrogen, Carlsbad, CA, USA). 
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Immunoassays    
Gastrin was analyzed using antiserum the C-terminally-directed CCK/gastrin antiserum 2609/10 
24. Chloramine-T labeled and HPLC-purified gastrin-17 (NeoMPS, Strasbourg, France) was 
used as radioligand and gastrin-17 as calibrator/standard. The assay reacts 100% with gastrin-
17 in plasma but not with pentagastrin. The detection limit of the assay was 3 pmol L-1 and 
the intra-assay coefficient of variation 6%.    
Somatostatin was analyzed using an enzyme immunoassay kit (EK-060-03, Phoenix 
Pharmaceuticals, Burlingame, CA, USA), which reacts 100% to somatostatin-14, -25 and -28 in 
plasma. The intra-assay coefficient of variation was 5%. 
For ghrelin measurements the rat ghrelin (active) enzyme-linked immunosorbent assay kit 
(EZRGRA-90K, Millipore, Billerica, MA, USA) was used, that utilizes 125I-labeled ghrelin 
and ghrelin antiserum which reacts 100% to active ghrelin in plasma, but not to inactive des-
octanoyl ghrelin. The intra-assay coefficient of variation was 7%. 
 
Real-time quantitative polymerase chain reaction 
Real-time qPCR was performed on an ABI 7300 Real-Time PCR System (Applied 
Biosystems, Foster City, CA) using TaqMan gene expression Mastermix (TaqMan®, Applied 
Biosystems Europe BV, Stockholm, Sweden) for gastrin, somatostatin, ghrelin, iNOS, and for 
the receptors CCK2, ghrelin receptor, and SSTR2 (gene expression assays no. Rn01644838, 
Rn00561967, Rn00572319, Rn00561646, Rn00565867, Rn00571116, Rn00583419; amplicon 
lengths 60, 117, 82, 77, 109, 91, 78 respectively). Primers were purchased as primer set 
optimized for TaqMan gene expression assay (TaqMan®, Applied Biosystems Europe BV). 
The expression in each reaction was normalized by the expression of hypoxanthine 
phosphoribosyl transferase 1 (Hprt1) (gene expression assay no. Rn01527840, amplicon 
length 64) as internal control.  
Complementary DNA subjected to real-time qPCR was performed in 25 µL reaction volumes 
consisting of 20 x TaqMan universal PCR master mix (Applied Biosystems Europe BV). 
Amplification was carried out at 50° C for 2 min, 95° C for 10 min, 50 cycles of 95° C for 15 
sec, and 60° C for 1 min. The absolute amounts of transcripts were determined by using 
several concentrations of standard cDNA (1000, 100, 10, and 1 ng) that were reverse 
transcribed from the stomach of Wt naive males. qPCR analyses were performed in triplicate 
of each sample and standards included in each experiment. 
 
Data analysis and statistical analysis 
The data obtained with the Bravo capsule was analysed using the POLYGRAM NET ™ (pH 
Testing Application software, Synmed Medicinteknik) in 48-h periods. Results of studies with 
YF476 and pentagastrin were analyzed by calculating changes in pH at various timepoints 
from baseline (defined as 0.5 h prior to onset). The qPCR measurements were calculated 
using the 2(-DeltaDelta C(T)) method25.  
All data are expressed as mean±SEM. Data were compared using a one-way analysis of 
variance followed by a Dunnett´s multiple comparison test or Mann-Whitney test. P less than 
5% was considered significant. 
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Results 
 
Intragastric pH. The collective data shown in figure 1 describes the pH changes during a 24-h 
period. Under control conditions, the average 24-h pH was 2.3 ±0.6 with a variation of 19 
±4% over the 5-day study period. After administration of YF476 (100 mg kg-1) gastric pH 
significantly increased from baseline 2.1 ±0.3 to 3.5 ±0.3 already after the first dose. This 
difference in pH was maintained throughout the study period (P <0.001). There were no 
significant differences between diurnal pH changes (9 am to 3 pm vs 3 pm to 9 am) when 
YF476 was given, except that pH was maintained at a higher level. 
 
Gastroprotection. As seen in figures 2C and 2D the macroscopic appearance revealed 
gastroprotective properties of YF476 comparable to those of esomeprazole on diclofenac-
induced gastric ulcers (Fig. 2A). This was reflected by the ulcer index (Fig. 3), which 
markedly diminished in the groups receiving YF476 (4.8 ±2.4 mm; P <0.001) or 
esomeprazole (5.4 ±1.1 mm; P <0.01), as compared to controls (70 ±14 mm). 
 
Stomach regulatory peptides. Administration of YF476 (100 mg kg-1) significantly increased 
ghrelin and, somatostatin, but not gastrin as compared to control. Ghrelin increased 12-fold 
compared to control from 17 ±7 to 211 ±12 pmol L-1; P<0.001), while somatostatin increased 
6-fold from 42 ±6 to 260 ±23 pmol L-1; P <0.001) (Fig. 4). 
 
Gene expression of stomach peptides and receptors. As shown in figure 5, when YF476 was 
given there was a great variability and no significant changes of the expression of gastrin, 
ghrelin, or somatostatin in gastric tissue, or the corresponding receptors, except for the 
expression of the ghrelin receptor which decreased (p=0.026) compared to internal control. 
 
Gastroprotection and gene expression. After diclofenac the gene expression of iNOS 
increased 30-fold (P<0.01), the expression of gastrin and its receptor increased more than 
300-fold (P<0.01), and 18-fold (P<0.05), respectively. The expression of ghrelin and 
somatostatin or their receptors did not change (Fig 6). 
 
Discussion  
 
YF476 is a member of a new class of drugs, the so-called CCK2-receptor antagonists, which is 
believed to counteract the effects of gastrin on parietal cells and ECL-cells that are shown to 
express the CCK2-receptor on their surface. Hence, it is expected that treatment with YF476 
should result in a diminution in gastric acid secretion and reduction of certain symptoms and 
pathogenic mechanisms of acid peptic diseases or upper gastrointestinal disorders26.  
Our study shows that YF476 administered twice daily increased gastric pH up to about 3.5. 
This took place with a limited variability and no indication of decreased sensitivity to the drug 
over five days in a row. Studies of experimental NSAID-induced gastric ulcerations further 
showed a gastroprotective effect of YF476 comparable to that of esomeprazole. Long-term 
treatment with YF476 under challenge with pentagastrin increased the plasma concentrations 
of ghrelin and somatostatin, whereas plasma gastrin was only barely elevated not reaching 
statistical significance. At the same time mRNA expressions of gastrin, ghrelin and 
somatostatin did not change after exposure to YF476. Of the corresponding receptors the 
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ghrelin receptor decreased, whereas the CCK2-receptor and SSTR2 were unchanged. On the 
other hand, NSAID-induced ulcerations as characterized by increased gene expression of 
iNOS, revealed an up-regulation of both gastrin and the CCK2-receptor, while neither ghrelin 
nor somatostatin or their receptors were changed. 
 
The ECL-cell of the oxyntic mucosa is functionally related to acid secretion through a 
paracrine release of histamine which activates the parietal cell. The ability of the ECL-cell to 
undergo proliferation in response to the trophic stimulus of hypergastrinemia has important 
implications in pathology, being involved in the development of ECL-cell carcinoid tumors of 
rodents treated with powerful inhibitors of acid secretion27. In addition, most human gastric 
carcinoids are composed of ECL cells28. Hence, the ECL-cell response to gastrin in humans 
has contributed to the development of CCK2-receptor antagonists, assumed to counteract 
effects of the hypergastrinemia caused by inhibition of acid secretion. CCK2-receptor 
antagonists act by blocking the gastrin receptor leading to a reduction in histamine elaboration 
and release29. We found that YF476 inhibited acid secretion thereby increasing pH to a level 
high enough to prevent gastric damage of NSAID. This finding speaks in favour of a 
pharmacologically applicable use of the compound. At the same time there was a limited 
increase of circulating gastrin perhaps due to the acid inhibitory effect of the drug30. Our data 
also show that circulating somatostatin was increased during YF476 treatment which might 
further reduce local gastrin release from G-cells31,32. The biological significance of the 
parallel increase of ghrelin is unclear but is likely to represent another component of the local 
acid regulatory mechanisms33. Previous research by our group has also found ghrelin IV to 
increase somatostatin34. This opens the possibility that ghrelin apart from food intake, also 
affects secretory functions implying a multifacetted role in nutritional intake and digestion. 
Long-term administration of YF476 increased the mRNA expression of the CCK2-receptor, 
the ghrelin receptor, and SSTR2 most markedly of the CCK2-receptor. Due to this, it can be 
argued that the changes in receptor expression may reflect a compensatory adjustment or 
mobilization of CCK2-receptor because of inhibition of that same receptor by YF476. 
Considering the localization of CCK2-receptor, on parietal cells as well as ECL cells5, seem to 
be main targets for inhibition acid secretion in order to avoid compensatory endocrine 
hypersecretion or receptor expression35. The variability of gut peptides and receptor 
expression between different animals in this study is compelling, but may reflect a natural 
condition with a high variability between different individuals as regards their sensitivity to 
stimulation of gastric acid secretion and regulatory peptides.  
 
In order to disentangle inflammatory gene expression patterns involved in the ulcer-inducing 
capacity of diclofenac we found that not only mRNA of iNOS was increased, but also 
expression of gastrin and CCK2-receptor. These alterations speak in favour of an up-
regulation of a local gastrin-CCK2-receptor link, which might be of additional importance for 
the development of NSAID-induced ulcers. Thus, the CCK2-receptor blocker YF476 would 
here find another mechanism of action. In agreement with this, Walduck et al. have found that 
there is a cyclooxygenase (COX)-2 dependent subset of genes, some of which directly 
influence gastric physiology (Gastrin, Galr1), epithelial barrier function (Tjp1, connexin45, 
Aqp5), inflammation (Icam1), apoptosis (Clu) and proliferation (Gdf3, Igf2). Under treatment 
with NSAID there is a differential expression of 140 genes, 97 of which seem unique, 
indicating that these genes are regulated only under COX-2 expression36. Moreover, gastrin 
increases the stability of COX-2 mRNA increasing its half-life increasing from 0.5 to 8 h and 
enhances COX-2 mRNA binding. In addition, data in vitro suggest that gastrin transactivates 
the COX-2 promoter in cells expressing the CCK2-receptor and can further increase COX-2 
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expression37. In line with our results, there seems to be a panel of COX-2 dependent genes to 
which the gastrin gene38 and the CCK2-receptor gene39 can be added. As the same gene 
profiles are present in humans40, these data provide important new links between COX-2, the 
inflammatory processes, epithelial repair and integrity 
In conclusion, gastric acid secretion was inhibited by the CCK2-receptor antagonist YF476. 
This promotes mucosal healing with a numerical increase of plasma gastrin and further 
increases of ghrelin and somatostatin, while tissue mRNA expression of the ghrelin receptor 
increases. Under treatment with NSAID, the mRNA expression of the peptide gastrin as well 
as its receptor, CCK2-receptor are up-regulated suggestive of a local coupling link between 
gastrin, the CCK2-receptor and COX-2 in the pathogenesis of NSAID-induced gastropathy. 
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Figure legends: 
 
Fig. 1. Change in mean pH±SEM in the Bravo system during ad libitum conditions after bolus 
dose of YF476 (100 mg kg-1 intragastrically) under continuous pentagastrin stimulation (90 
pmol kg-1min-1) for 6 h from 9 am to 3 pm and then from 4 pm to 8 am the following day; 
repeated for five consecutive days (*** P<0.001). 
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Fig. 2A-D. Representative photographs of excised rat stomachs 4 h after different challenges.. 
(A) shows positive control given saline 1 h prior to administration of diclofenac (30 mg kg-1) 
with saline, (B) represents the negative control were animals received saline alone, (C) shows 
the preventive effect of esomeprazole (140 mg kg-1) and (D) the comparative effect of  YF476 
(100 mg kg-1) given in the same fashion as the saline control.(cf. A). 
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Fig. 3. Effect of esomeprazole and YF476 on gastric ulcer induced by diclofenac (30 mg kg-
1). Both esomeprazole (140 mg kg-1) and YF476 (100 mg kg-1) was given 1 h prior to the 
administration of diclofenac and compared to saline control, all by means of gavage. Ulcer 
index was determined 4 h after administration of diclofenac. Values are expressed as mean 
±SEM (**P<0.01, ***P<0.001). 
 
 
 
 
Manuscript Rudholm 16 
CG CGh CS G Gh S
0
100
200
300
400
500
600
700
800
900
1000
***
***
P
ep
ti
d
e 
co
n
ce
n
tr
at
io
n
 (
p
m
o
l 
L
-1
)
 
Fig. 4. Peptide concentrations in plasma expressed as mean ±SEM after administration of 
YF476 (100 mg kg-1 intragastrically) compared to controls. C (Control), G (gastrin), Gh 
(ghrelin), and S (somatostatin). (*** P<0.001). 
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Fig. 5. Effects of bolus dose YF476 (100 mg kg-1 IV) and infusion of pentagastrin (90 pmol 
kg-1min-1 IV) on the mRNA expression of different gut peptides and their receptors. Values 
are expressed as mean fold change in gene expression ±SEM (* P=0.0260). CCK2 
(cholecystokinin-2 receptor), SSTR2 (somatostatin receptor-2). 
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Fig. 6. Effects of bolus dose YF476 (100 mg kg-1 IV), esomeprazole (140 mg kg-1) and 
control (saline) followed 1 h later by diclofenac (30 mg kg-1) on the mRNA expression of gut 
peptides, their receptors, and iNOS. All drugs were given by gavage The values are expressed 
as mean fold change in gene expression ±SEM; * P=0.0260 (CCK2-receptor) ** P=0.0079 
(Gastrin), ** P=0.0043 (iNOS). CCK2 (cholecystokinin-2 receptor), SSTR2 (somatostatin 
receptor-2), iNOS (inducible nitric oxide synthase). 
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Abstract 
 
Background: Neuropeptide S (NPS) is expressed by gastrointestinal (GI) enteroendocrine 
cells in rat and man. Effects of NPS are mediated through the NPSR1 receptor and associated 
with anxiety and nociception, as well as increased risk of inflammatory bowel disease. 
Polymorphisms of the NPSR1 receptor are linked to motor and sensory disturbances of the 
gut suggesting a role for NPS in functional GI disorders. We studied effects of NPS infusion 
on fasting small bowel motility, and expression of tumor necrosis factor (TNF), interleukin-1 
beta (IL-1 beta) and inducible nitric oxide synthase (iNOS) as biomarkers of inflammation. 
Methods: Studies of migrating myoelectric complexes (MMCs) were carried out in rats with 
electrodes implanted in the small bowel, and a jugular vein catheter. After baseline recording 
of 60 min with four activity fronts, NPS was infused IV for 60 min. Myoelectric activity was 
recorded using a Grass Polygraph with EEG preamplifiers. Tissue samples were obtained for 
evaluation of gene expression of TNF, IL-1β and iNOS. 
Results: NPS at low dosage (1000 pmol kg-1min-1) increased irregular spiking, while high 
dosage (2000 and 4000 pmol kg-1min-1) significantly reduced spiking activity and increased 
the MMC cycle length (P=0.0152 and P=0.0022, respectively). NPS (4000 pmol kg-1min-1) 
induced 1.8 to 2.6-fold increase in mRNA expression of TNF and IL-1β, although less than 
diclofenac. iNOS expression was numerically increased by 1.4-fold. 
Conclusion: NPS is involved in motility responses of the small intestine when administered 
peripherally and does so in a dose-response manner. NPS seems capable to increase cytokines 
as inflammatory markers. 
 
Key words: Inflammation, migrating myoelectric complex, MMC, biomarkers, nitric oxide
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Introduction 
 
Neuropeptide S (NPS) is a recently discovered neuropeptide that is highly expressed in 
different regions of the central nervous system and gastrointestinal (GI) tract1. Its effects are 
mediated through the NPSR1 receptor, which expression parallels that of NPS in various 
tissues1,2. There is strong evidence that NPS promotes anxiolytic-like effects in rodents1-5, 
increases wakefulness, suppresses sleep and induces hyperlocomotion3,6. NPS also either 
inhibits7 or stimulates8 food intake through orexin-containing neurons, and is considered to be 
involved in inflammatory reactions9. Effects of NPS are mediated through the receptor 
NPSR1 and increase the mRNA expression of cholecystokinin, vasoactive intestinal peptide, 
peptide YY and somatostatin10. Polymorphisms of the NPSR1 have been associated with 
motor and sensory disturbances, such as hastening of colonic transit, as well as pain, gas, and 
urgency sensations upon distension of the gut suggesting a role for NPS in functional GI 
disorders11. 
The aim of this study was to examine the effect of prolonged NPS infusions in a broad dose 
range on the fasting motility pattern, as well as on the gene expression of the cytokines 
tumour necrosis factor (TNF) and interleukin (IL)-1β and inducible nitric oxide synthase 
(iNOS) as biomarkers of an inflammatory response. 
 
Material and Methods 
 
Animals 
Sprague-Dawley male rats (n = 42; 300-350 g) were purchased from Scanbur AB (Sollentuna, 
Sweden). The rats were housed in wire-meshed cages at 24° C with constant humidity and 
12:12 h light-dark cycle. The animals were allowed to acclimatize to the new environment at 
the animal facility, and were fed ad libitum with a commercial rat diet consisting of pellets 
(LABFOR, Lactamin R36, Kimstad, Sweden) and tap water prior to the studies. The 
experiments were approved by the Animal Ethics Committee in northern Stockholm (diary 
no. 226/09:348/09; 20091116 – 20100315). 
 
Surgical procedure 
Surgery was performed in 30 rats under anesthesia with a mixture of midazolam (5 mg ml-1, 
Aktavis AB, Stockholm, Sweden) and Hypnorm (fentanylcitrate, 0.315 mg kg-1 plus 
fluanisone 10 mg kg-1; Janssen-Cilag, Oxford, CT, USA.) given subcutaneously (SC) at a 
dose of 1.5-2 ml kg-1 body weight. Temgesic® (Schering-Plough, Stockholm, Sweden) 0.05 
mg kg-1 body weight was given SC after surgery to avoid post-operative pain. 
The abdomen was opened via a midline incision. The animals were then supplied with three 
bipolar insulated stainless steel electrodes (SS-5T; Clark Electromedical Instr., Reading, UK) 
implanted into the muscular wall of the small intestine, 5 (J1), 15 (J2) and 25 (J3) cm distal to 
the pylorus. All animals were supplied with an indwelling silastic catheter (Dow Corning Co., 
Midland, MI, USA) inserted into the external jugular vein for intravenous (IV) administration 
of NPS. The electrodes were pierced through the abdominal muscle wall and together with the 
vein catheter tunneled to the back of the animal’s neck. After surgery, the animals were 
housed individually and allowed to recover for at least 7 days before experiments were 
undertaken. All animals were monitored daily. 
 
Experimental procedures 
Small bowel motility.  Experiments were carried out in conscious animals after an overnight 
fasting period in wire-bottomed cages with free access to water. The rats were placed in 
Bollman cages during the experiments, and the electrodes were connected to 
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electroencephalography preamplifiers (7P5B) operating a Grass Polygraph 7 B (Grass Instr., 
Quincy, MA, USA). The main characteristic feature of myoelectrical activity of the small 
intestine in the fasted state, the activity front (phase III) of the migrating motor complex 
(MMC), was identified as a period of clearly distinguishable intense spiking activity with an 
amplitude at least twice that of the preceding baseline and a frequency of at least 40 spikes 
min-1, propagating aborally through the whole recording segment and followed by a period of 
quiescence, phase I of MMC. The MMC cycle length, duration and propagation velocity of 
the activity fronts were calculated as a mean of the study period. The MMC cycle length, 
reflecting the interval between the propagated activity fronts was calculated at the J2 
recording site. All experiments started with a control recording of baseline myoelectric 
activity over a period of about 60 min with four regular MMCs propagating over all three 
recording sites. As the fifth activity front had vanished at the first electrode site, an IV 
infusion of either NPS(NeoMPS, Strasbourg, France) at doses of 100, 300, 1000, 2000 or 
4000 pmol kg-1min-1 (each dose, n=6), or saline solution (sodium chloride 9 g L-1; 300 
mosm/kg H2O, Fresenius Kabi, Halden, Norway) (n = 6) was started using a microinjection 
pump (CMA 100; Carnegie Medicine, Stockholm, Sweden) and continued for 60 min, after 
which the experiment continued until the basal MMC pattern returned (within a total 
experiment time of 6 h). 
 
Tissue sampling and RNA isolation. Twelve rats were challenged with NPS at a dose of 4000 
pmol kg-1 min-1 IV during 60 min. At the end of experiments animals were euthanized with 
pentobarbital (Apoteksbolaget, Solna, Sweden). Tissue segments (20-30 mg) were collected 
from the corpus of each animal, quickly placed in RNA stabilizing reagent (RNA-later, 
Ambion, Applied Biosystems, Austin, TX, USA) and stored at 4° C for 24 h before storage in 
-20° C freezer preceding real-time PCR analysis. The tissue samples were then placed in RTL 
cell lysis buffer (Qiagen, Hilden, Germany) and homogenized by means of a rotor-stator knife 
(Ultra-Turrax T8, IKA®-Werke, Staufen, Germany). Total RNA was extracted using the 
RNeasy Mini Kit according to the manufacturer’s instruction (Qiagen). Finally, a DNase 
digestion step using DNase I (Promega, Madison, WI, USA) with incubation at 37° C for 30 
min was included to remove traces of DNA. 
Samples with A260/A280 ratio ≥1.8 were used for PCR. Complementary DNA (cDNA) 
synthesis was performed on 1-5 µg of total RNA using oligo dT primers and Superscript III 
reverse transcriptase (Invitrogen, Carlsbad, CA, USA) at temperatures 25° C for 10 min, 42° 
C for 50 min, 70° C for 15 min, respectively. 
 
Real-time quantitative polymerase chain reaction. mRNA expression of TNF, IL-1β and 
iNOS was analyzed using real-time quantitative polymerase chain reaction (qPCR) performed 
on an iCycler iQ real-time detection system (Bio-Rad Labs, Hercules, CA, USA). Primers 
(TNF, IL-1β) were designed according to literature12 or our previous experimentations 
(iNOS)13 and manufactured by CyberGene® (Stockholm, Sweden) (Table 1). PCR reaction 
mixture was prepared using QuantiTect SYBR Green PCR Master Mix (Qiagen). Each 
sample was analyzed in triplicate according to the manufacturer’s instructions (Qiagen). For 
each reaction, melting curves were generated to verify the identity of amplification product. 
Thermal cycling conditions were 13 min at 95° C to activate the HotStarTaq DNA 
polymerase, followed by 40 cycles of 95° C for 15 s, 60° C for 30 sec, and 72° C for 20 sec. 
The expression of each gene was normalized to 18S mRNA content and calculated relative to 
control using the 2-ΔΔCt method14.  
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Statistical analysis 
All values are expressed as mean ±SEM. Mann-Whitney test were used when comparing the 
MMC cycle length, duration and velocity and in the fold expression changes in the qPCR 
analysis. P <0.05 was considered statistically significant. The Prism software package 4.0 
(GraphPad Software Inc., San Diego, CA, USA) was used for the statistical comparisons. 
 
Results 
 
Small bowel motility. Infusion of NPS (100-4000 pmol kg-1min-1) changed the appearance of 
the myoelectric activity and the MMC cycle length. In the lower dose range irregular and 
sporadic myoelectrical spiking was induced (Fig. 1), while higher dosage range also 
prolonged the MMC cycle length in a dose-dependent manner (Fig. 1, 2, Table 2). NPS at 
2000 pmol kg-1min-1 signficantly prolonged the cycle length, which was even more marked at 
4000 pmol kg-1min-1. At the same time the duration of the activity front was dose-dependently 
increased while the propagation velocity was not changed (Table 2). 
 
Expression of inflammatory markers TNF, IL-1β and iNOS. As shown in table 3 NPS at 4000 
pmol kg-1min-1 for 60 min, induced an 1.8 to 2.9-fold increased mRNA expression of TNF, 
IL-1β, and iNOS compared to internal control. All results showed a considerable variation.  
 
Discussion 
 
Our present investigation demonstrates that peripheral infusion of NPS evokes a motility 
response in the small intestine. Firstly, at low doses irregular spiking was induced, and 
secondly the MMC cycle length increased to at least a doubling of the interval between the 
activity fronts. To this end, our studies showed NPS to be capable of inducing a numerical 
increase of the recognized inflammatory biomarkers TNF, IL-1β, and iNOS. 
In the rat, the NPS receptor is expressed in the autonomic nervous system and GI tract2,15, 
which suggests a role for NPS and its receptor (NPSR) in the regulation of GI functions. 
Hence, NPS has been reported to have an effect on food intake7,8, which is influenced on GI 
motility primarily gastric emptying16-20. Thus an effect on GI motility is at hand as evidenced 
by our present findings of increased spiking activity of the small bowel as well as prolonged 
MMC cycle length. In addition to effects on physiological conditions, the NPS receptor is 
associated with susceptibility for inflammatory bowel disease21. Irregular spiking is 
commonly seen in inflammatory conditions, be it direct22,23 or indirect24. In agreement with 
this Han et al.25 found that NPS administered intracerebroventricularly inhibits colonic transit 
implying a motility effect in the gut. For comparison, the same authors found no in vivo 
effects of NPS when given intraperitoneally even at high dosages up to about 100 times those 
used in our experiments, or in studies in vitro. These results are inconsistent with ours, even if 
we used a comparably high dosage of NPS as compared to other gut peptide hormones or 
neuropeptides to achieve a motility response26-30. This fact is in agreement with a paracrine or 
neurocrine effect of NPS, rather than an endocrine effect, and also seems to fit with the 
general concept of NPS as a neuropeptide.  
In order to bring about a physiological motility effect of NPS its receptor has to be localized 
in the intestines. Recent data show that the receptor variant NPSR1-A mRNA is expressed by 
enteroendocrine cells in the gut. Challenge with NPS results in up-regulation of peptides such 
tachykinin 1, neurotensin and galanin which encode peptide hormones to be liberated by 
enteroendocrine cells. Moreover, challenge with pro-inflammatory cytokines, such as TNF 
and interferon-beta increased NPSR1 expression in monocytes1. These findings also seem to 
have a bearing on humans since NPS and NPSR are expressed in colon as shown by in situ 
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hybridization31 and can stimulate cell proliferation and mitogenic signals in human colon 
cancer cells32. 
As the NPS/NPSR system previously has been associated with the risk of developing 
inflammatory bowel disease we sought to investigate whether challenge with NPS is able to 
induce an inflammatory response. In our study, NPS given at a dose and during a period that 
evokes a motility response did not invariably cause an increase of the cytokines TNF, IL-1b, 
and iNOS. This does not unambiguously speak in direction of NPS as an inflammatory 
mediator. 
Recently, antagonists for the NPSR were identified33,34. Since the antagonist was found to 
have no effect on basal motility but inhibited the response to exogenous NPS, it seems that 
NPS is not constantly tonically active, but may be activated under certain circumstances to 
target a particular function. This data fits with the idea of NPS being associated with 
inflammatory reactions. However, even though our present study could not conclusively 
support this picture in terms of cytokine increase, the observed increase in iNOS may be of 
interest as inducible NO production seems detrimental during acute colitis, but sustained up-
regulation of NO is beneficial in terms of IBD35,36. Comparative data using diclofenac to 
trigger gut injury clearly disclosed an inflammatory reaction with an immense increase of 
iNOS expression (III). 
In conclusion, peripheral NPS brings about a motility response in the gut similar to that 
observed in endotoxinemia and inflammatory reactions, whereas the early response to NPS 
did not invariably cause an inflammatory response why prolonged activation of the 
NPS/NPSR system may be needed to incite a chronic inflammation in the gut. 
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Figure legends: 
 
Fig. 1. Electromyographic recording showing the effect of Neuropeptide S on the 
myoelectrical activity of the small intestine. Upper panel: After four activity fronts of the 
migrating myoelectric complex under fasting conditions, infusion of neuropeptide S was 
started and continued during 60 min (arrow with broken/solid line). Middle panel: During 
infusion of Neuropeptide S at 2000 pmol kg-1min-1 intravenously (IV) irregular spiking was 
induced followed by prolongation of the interval between activity fronts. Lower panel: Upon 
termination of infusion there was a slow recovery of the intestine until recurrence of activity 
fronts. 
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Fig. 2. Effect of infusions of neuropeptide S and saline on the cycle length of the migrating 
myoelectric complex in fasting small bowel motility. Infusions of saline or NPS (100, 300, 
1000, 2000 or 4000 pmol kg-1min-1) were administered for 60 min. Results are mean ±SEM 
(*P=0.0152; **P=0.0022). 
 
 
   
 
Table 1. Primers of the target genes studied. 
Gene product Forward (5´-3´) Reverse (5´-3´) 
TNF GACCCTCACACTCAGATCATCTTCT ACGCTGGCTCAGCCACTC 
IL-1β GAAAGACGGCACACCCACC AAACCGCTTTTCCATCTTCTTCT 
iNOS CACCTTGGAGTTCACCCA  ACCACTCGTACTTGGGATGC 
iNOS, inducible nitric oxide; IL-1β, interleukine-1β; TNF, tumor necrosis factor 
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Table 2. Characteristics of MMC during infusion of neuropeptide S. 
Interval Duration Velocity   
Study group (min) (min) (cm min-1) 
    
NPS Control period 11.4±0.4 3.9±0.3 1.9±0.2 
Infusion of NPS (100 pmol kg-1min-1) 12.3±0.6 3.7±0.2 1.7±0.2 
    
NPS Control period 10.3±0.6 4.0±0.3 1.7±0.2 
Infusion of NPS (300 pmol kg-1min-1) 10.9±1.0 3.7±0.3 1.9±0.2 
    
NPS Control period 11.9±1.1 4.1±0.5 1.8±0.2 
Infusion of NPS (1000 pmol kg-1min-1) 12.4±1.4 5.6±0.3 1.6±0.1 
    
NPS Control period 10.5±0.8 4.4±0.2 2.0±0.2 
Infusion of NPS (2000 pmol kg-1min-1) 15.8±1.4* 11.2±0.4** 1.8±0.2 
    
NPS Control period 11.3±0.9 3.6±0.2 2.0±0.2 
Infusion of NPS (4000 pmol kg-1min-1) 23.9±2.2** 12.4±0.7** 1.7±0.1 
NPS, neuropeptide S. Values are mean ± SEM for all MMC cycles during the respective period. NPS = 
neuropeptide S. *P = 0.0152 (interval), **P = 0.0022 (interval and duration). 
 
 
 
 
Table 3.  Messenger RNA expression of target genes under challenge with neuropeptide S. 
Gene Mean fold change 
in gene 
expression  
 
TNF  2.6 ±2.4 
IL-1β 1.8 ±1.2 
iNOS  2.9 ±0.9 
Data analysis using the 2-ΔΔCt method (13). Effects of  infusion of neuropeptide S (4000  
pmol kg-1min-1 IV) for 60 min on the mRNA expression of inflammatory biomarkers. Values are  
expressed as mean fold change of gene expression ±SEM.   

